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THE CELLULAR ORIGIN AND MOLECULAR DRIVERS OF
CLAUDIN-LOW MAMMARY CANCER
Patrick Dominik Rädler, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor: Kay-Uwe Wagner, Ph.D.
Breast cancers of the claudin-low subtype make up a substantial portion of triple-negative
breast cancers and have stem cell-like and mesenchymal features. Although it has been
recognized for some time that this breast cancer subtype is highly aggressive and difficult
to treat, the molecular drivers and cellular origin of claudin-low breast cancer have been
poorly defined. The lack of suitable in vivo models has prohibited the study of tumor
initiation and progression of this subtype. In this work, we report two novel mouse
models that, upon expression of oncogenic RAS in the mammary epithelium, develop
highly metastatic triple-negative mammary tumors that belong to the claudin-low
subtype. The main technological advance of these models is that we uncoupled the
expression of the oncogene from differentiation-state dependent promoters, which
uncovered a remarkable range of cellular plasticity that mammary tumor cells can assume
during cancer progression. Specifically, when mutant KRAS is expressed under its own
gene locus or another ubiquitously active promoter in luminal epithelial cells, we
observed that cancer cells engage a continuous transdifferentiation program that promotes
epithelial-to-mesenchymal transition (EMT), which ultimately lead to the development of
undifferentiated, mesenchymal and stem cell-like mammary cancers. The longitudinal
study revealed that claudin-low mammary cancers can progressively evolve from luminal
cells that transition through basal-like neoplastic lesions and tumors before reaching a
mesenchymal-like differentiation state. Moreover, we demonstrated that the continuous
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signaling of oncogenic RAS in cooperation with regulators of EMT plays a crucial role in
the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics
of claudin-low mammary cancer cells. In summary, we have shown that claudin-low
mammary cancers can arise from functionally differentiated luminal cells and, therefore,
this cancer subtype does not exclusively originate from normal undifferentiated
mammary stem cells as previously proposed. Moreover, we established that hyperactive
RAS signaling plays an important role in claudin-low breast cancer biology and may
serve as a suitable target for breast cancer prevention, diagnosis, and treatment.
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Chapter 1: Introduction
1.1 The historical origin of breast cancer
In 1862, a papyrus dating to the 17th century B.C. was discovered near Luxor, Egypt and
was sold that same year to the antiques dealer Edwin Smith1. This papyrus, nowadays
known as the Edwin Smith papyrus, remained untranslated despite multiple attempts until
the year 1930, when James Henry Breasted published its translation in two volumes2. It
turned out to be the oldest known surgical record in the history of civilization. While the
papyrus itself dates to the 17th century B.C. the original manuscript was written around
3000 to 2500 B.C. and is suspected to have been produced by Imhotep, the earliest
known physician. What makes this papyrus particularly remarkable is that it provides the
oldest known account of breast cancer and describes the disease as “Bulging Tumors on
the Breast” (Case 45 of the Edwin Smith papyrus). Breasted commented on case 45 that
these bulging tumors were the result of a disease and not as mentioned in other cases a
result of injury. The “Bulging Tumors of the Breast” are described by the original author
as swellings on the breast that are hard, cool, large and spreading. According to the
translation, the author of the original manuscript concluded: “There is no treatment. If
thou findest bulging tumor in any member of a man, though shalt treat him according to
these directions”. The recommended treatment was therefore the omission of treatment.
For a long time since this first description, breast cancer was a rather mysterious
disease and was subject to many theories regarding its cause and origin. One of the most
prominent theories came from Galen (130-200 A.D.), a Roman physician that proposed
breast cancer arises from the accumulation of excess black bile in the breast3. This theory
was upheld for almost 1,500 years but was challenged with the dawn of the scientific
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method and modern medicine in the 17th and 18th century. During this time René
Descartes (1596-1650) proposed that breast cancer originates from abnormalities of the
lymph (lymph theory)4, a suggestion that was further reinforced by John Hunter (1728–
1793)3. Hunter, credited to be the first scientific surgeon, believed that breast cancer
results from coagulation of flawed lymph in the breast5. While these theories resulted in
the surgical removal of the lymph nodes and could therefore improve the patient’s
outcome, the lymph theory was not meaningful to advance the care of breast cancer
patients significantly. Many more or less popular theories started circulating during these
times about the origin of breast cancer, but no real progress was made until 1838 when
the German pathologist Johannes Müller proposed that breast cancer arises locally in the
breast from blastema (a formless, fluid exudate within existing cells) of the normal tissue
and not from the lymphatic system6,7. Not long after, Müllers’ scientific successor Rudolf
Virchow (1821–1902) first popularized the idea of “omnis cellula e cellula” (all cells
come from cells) and inferred from this idea that cancers also originate from initially
normal cells8. He had shown through the use of microscopy that cancers, among them
breast cancers, were composed of cells and stated “In diseased conditions pathological
substitutions occur, in which a given tissue is replaced by another; but even when this
new tissue is produced from the previously existing one, the new formation may deviate
more or less from the original type”9. He therefore recognized that cells arise from cells
but that these cells may deviate from their original cell, which led him to conclude that
the origin of cancer cells is an initially normal cell.
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1.2 The origin of clinical breast cancer subtypes
While Virchow’s concept that cancers arise from normal cells gained more and more
popularity the first observations were made that breast cancer might not be a homogenous
disease but that there are significant variations that can have a profound impact on patient
outcome. In 1874, after graduating from the University of Edinburgh, George Thomas
Beatson lived on an estate in Scotland adjacent to a large sheep farm where he became
fascinated with the weaning of lambs and the process of lactation10. His interest went so
far that he decided to take a closer look at lactation for his M.D. thesis and learned that
lactation in cows was prolonged virtually indefinitely by removing their ovaries after
calving. Upon closer inspection of the mammary gland during different stages of
mammary gland development, Beatson soon noticed the enormous amount of
proliferation that the mammary gland undergoes to reach the lactational stage11. This
finding led him to reason that there is an association between the function of the ovaries
and the proliferation of epithelial breast cells. Beatson also noticed the parallels between
breast cancer and the cellular proliferation of the normal mammary gland during
pregnancy and noted that “lactation is at one point perilously near becoming a cancerous
process if it is at all arrested”. Initial successful testing on rabbits motivated Beatson to
assess if the ovaries had an impact on the growth of breast cancer. Thus, he performed a
bilateral ovariectomy on a 33 year old patient that presented with a large breast tumor
during her second pregnancy although the tumor had already appeared during her first
pregnancy11. The woman improved and survived for nearly 4 more years until she died of
recurrent disease. Beatson reported two more cases but did not continue pursuing this
idea further. However, Beatson’s initial success sparked the interest of other scientists
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such as Lett and Schinzinger12. Lett reported in 1905 that 24 out of 99 breast cancer
patients that had undergone an ovariectomy showed a marked response13. While the
removal of the ovaries showed some success in a subset of patients, the remaining
patients did not benefit from this treatment attempt. This was one of the first indications
that breast cancer might not be a homogenous disease as previously assumed and that
advanced and recurring tumors, in particular, cannot be universally treated.
Beatson had discovered the growth stimulating effects of the female ovarian
hormone, estrogen, on a subset of breast cancers before the hormone itself was
discovered in 192314. In the 1950s, Huggins and colleagues published a series of papers
that further demonstrated that a subset of patients with advanced breast cancer respond to
the ablation of sex hormones via the removal of the adrenal gland (adrenalectomy)15,16 or
the removal of the ovaries (oophorectomy)17. Based on these findings, they noted that
hormone depletion can induce regression of certain malignant tumors but is unable to
favorably influence other neoplastic growths that originate at the same site. Moreover,
they concluded that the functional characteristics of neoplasms vary greatly. This further
supported the idea that breast cancers, although arising in the same organ, can differ
significantly. Intertumoral heterogeneity was conclusively proven in a series of
subsequent reports in the 1960s by Elwood Jensen’s group. They discovered the estrogen
receptor (ER)18, and demonstrated that patients present with mammary tumors of varying
ER content19,20. Furthermore, they showed that ER content was predictive of response to
endocrine treatment, where patients with insignificant ER abundance did not respond to
endocrine therapy, while patients with significant ER content were responsive to such a
therapy. Not only did these findings confirm that there is substantial heterogeneity among
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breast tumors, but also that this heterogeneity can be predictive of treatment response.
Another hormone receptor, reported to bind to the other major ovarian hormone
progesterone, is the progesterone receptor (PR)21. While the biological impact of this
hormone receptor on breast cancer development and progression is controversial, the PR
has been shown to be a reliable readout for functional ER22. Because PR is an estrogen
regulated protein, it became the first prognostic marker of endocrine therapy response2224

. Multiple studies have indicated that ER positive breast cancers that also express PR

are much more likely to respond to endocrine therapy than PR negative tumors25. Today
PR serves as another immunohistochemical marker for the classification of breast
tumors26.
The 1980s brought forward another series of high impact publications that resulted in the
further separation of breast cancer types. With the discovery of the epidermal growth
factor receptor (EGFR)27, Stanley Cohen and colleagues laid the groundwork for the
discovery of the proto-oncogene human epidermal growth factor receptor 2 (HER2) also
known as Neu or ERBB228-30. Shortly thereafter, Stuart Aaronson’s group showed that
HER2 overexpression can cause uncontrollable growth of normal cells31 and detected
HER2 gene amplification in a human mammary carcinoma32. At the same, time Slamon
et al.33 reported that HER2 was amplified by 2- to more than 20-fold in 30% of human
breast cancers and showed that HER2 overexpression is a significant predictor for overall
survival and time of relapse. Finally, in 1988 William Muller et al.34 observed that the
overexpression of Neu in the mouse mammary gland was sufficient to initiate mammary
tumors and conclusively established the HER2 gene amplification as oncogenic in the
breast cancer. HER2 overexpression is independent of hormone receptor status and
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confers resistance to endocrine therapy even in the presence of hormone receptors35,36,
partially explaining the significant portion of breast tumors that do not respond to
hormone therapy. Together, these findings established another subset of breast cancer
that is initiated by the oncogenic overexpression of HER2 in the presence or absence of
the hormone receptors ER and PR.
To date, the profiling of ER and PR expression, and HER2 amplification in breast
cancer biopsies is standard clinical practice for the identification of the different clinical
subtypes37,38. This approach leads to three distinct, clinically relevant breast cancer
subtypes: (1) hormone receptor positive cancers that typically do not overexpress HER2
and make up about 68% of all breast cancer cases, (2) the HER2 amplified breast cancers
(~15% of all cases), and (3) the 10-20% of breast tumors that lack the expression of the
hormone receptors ER and PR and do not overexpress HER2. The latter are called triplenegative breast cancers (TNBCs). The subclassification of breast cancers into these three
broad tumor types is promoted by the current perception of their clinical usefulness as the
therapy intervention of early breast cancers is largely based on the expression of hormone
receptors and HER2 status39.
After researchers had discovered that a large portion of breast cancers are driven
by estrogen/progesterone signaling, and another sizable portion are propelled by the gene
amplification of HER2, the identification of therapeutic interventions soon followed.
Although initially developed as a contraceptive by ICI Pharmaceuticals (today
AstraZeneca)40, the antiestrogen drug ICI46,474 (now known as tamoxifen) showed
promising results in preventing the binding of estradiol to the estrogen receptor of
mammary tumors41,42. Moreover, the use of estrogen receptor assays in rat models and
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then in advanced human breast cancers could be used to predict response to
tamoxifen43,44. Because tamoxifen also displays some pro-estrogenic effects in the uterus
and vascular system that increase the risk of adverse effects, additional research was
conducted to target ER-ligand production instead of ER itself45. The result was the
discovery of aromatase inhibitors that block the conversion of androgens to estrogen.
This therapy is particularly useful in postmenopausal women with hormone receptor
positive breast cancer because the main source of estrogen in these women, once ovarian
function ceases, is the peripheral conversion of androgen to estrogen. Aromatase
inhibitors are, therefore, now the standard-of-care for postmenopausal women with
hormone receptor-positive breast cancers46. Thus, from a clinical perspective, it makes
sense to group breast cancers that are hormone receptor positive and rely on estrogen
and/or progesterone signaling into a distinct group since these tumors are anticipated to
respond to targeted endocrine therapy while the others are not. The same holds true for
HER2 amplified breast cancers. Herceptin, a targeted inhibitor against HER2, disrupts
oncogenic signaling specifically in breast cancers that show abnormally high levels of
HER2 and significantly improves patient outcome for women with this group of
tumors47. In 1998, Herceptin reached FDA approval for women with metastatic breast
cancer who have tumors that overexpress HER2, and in 2006, Herceptin was also FDAapproved for adjuvant treatment of HER2-positive, node-positive breast cancer, with the
goal of reducing metastatic spread and cancer recurrence. Triple negative breast cancers
(TNBCs), on the other hand, lack the expression of ER, PR, and do not have the
amplification of HER2, which renders them resistant to the aforementioned therapies.
Indeed, this group of breast cancers is difficult to treat and, at the same time, possesses
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the most aggressive tumor characteristics, resulting in the poorest patient outcome among
the three clinical subtypes48.
In summary, breast cancers are subtyped clinically based on currently actionable
clinical features (i.e., ER, PR, and HER2 status). While these clinical subtypes drive the
idea of breast tumor heterogeneity, they do not accurately reflect the much broader
spectrum of heterogeneity among breast cancers for which no specific clinical
interventions are approved or discovered yet, or for which the importance of certain
cancer cell features is still unknown.

1.3 The origin of modern molecular subtyping of breast cancer
The discovery of molecular subtypes of breast cancer in the first decade of the 21st
century has markedly influenced our understanding of intertumoral and intratumoral
heterogeneity. The scientific community caught on quickly that subtyping breast cancers
based on only a few tumor features may overlook other meaningful information. With the
advance of complementary DNA (cDNA) microarray technology to assess large parts of
the transcriptome in the late 1990s, interest flourished to characterize breast cancers
based on their gene expression profiles49. Aware that variation in transcriptional
programs accounts for much of the biological diversity of human cells and tumors, Perou
et al.50 characterized the variation in gene expression patterns of 65 surgically-obtained
breast cancer samples. Their initial observation based on the hierarchical clustering of
1,753 genes (out of the 8,102 analyzed) indicated that breast tumors display substantial
variation in their gene expression patterns and that these patterns are capable of reflecting
the relationships between genes and between tumors, as well as links between specific
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genes and specific tumors. Moreover, these gene expression patterns did not only reveal
similarities and differences between tumors, they also often reflected biologically
relevant processes such as cellular proliferation. Indeed, the largest cluster of genes
identified among the 1753 genes was the “proliferation cluster”, containing bona fide
proliferation genes (e.g., Ki-67, and PCNA). Commonly observed physiological variation
in growth rate, signaling pathway activation, and cellular composition of breast tumors
was all reflected in the corresponding variation of specific gene expression clusters.
Interestingly, molecular variation of normal mammary epithelial biology seemed to be
reflected in the analyzed breast tumors as well.
Human and mouse mammary glands are comprised of two main cell lineages –
basal/myoepithelial cells, and luminal cells – that are easily distinguished by lineagespecific markers (described in more detail in section 1.4). Gene expression analysis of the
breast cancers showed that many tumors expressed lineage-specific genes of one
epithelial cell lineage, but not the other (i.e., they express genes of luminal-lineage
markers but not of basal-lineage markers). Clustering based on these 1753 genes revealed
a spectrum of biological features and the relationships between tumor samples. However,
a major drawback in the selection of those genes was that a large subset of them reflected
the expression variation between samples from the same tumor (intratumoral variation).
Consequently, Perou et al.50 selected a subset of 496 genes that allowed for improved
detection of the gene expression variation between different tumors rather than between
paired samples from the same tumor. Ultimately this approach determined four distinct
groups of breast tumors that they associated with different molecular features of
mammary epithelial biology: (1) ER+/luminal-like, (2) basal-like, (3) ERBB2+, and (4)
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normal-like. This landmark study established that the diversity of breast cancers goes
beyond the clinical subtypes and that intertumoral heterogeneity is largely explained by
substantial variation of intrinsic molecular phenotypes among breast tumors. However,
the relatively small sample size suggested that the full spectrum of heterogeneity was yet
to be discovered. Indeed, a subsequent study by Sørlie et al.51 revealed that the luminallike intrinsic subtype can be further subdivided into at least two separate groups, which
they named luminal A, luminal B, and luminal C. The luminal intrinsic subtypes are
mostly characterized by their enriched expression of many bona fide luminal breast cell
genes. This luminal gene cluster includes an enrichment for luminal cell-typic genes such
as the estrogen receptor (ESR), GATA binding protein 3 (GATA3), X-box binding protein
1 (XBP1), hepatocyte nuclear factor 3a (FOX3A), trefoil factor 3 (TFF3), and estrogenregulated LIV-150,51. The luminal A subtype shows the strongest enrichment for these
luminal-specific genes, while the luminal B and luminal C subtypes express these genes
at more moderate levels. Furthermore, luminal B tumors show enrichment in proliferation
genes in comparison to the luminal A subtype52. Clinically, patients with the luminal A
subtype show a significantly better outcome than patients with the luminal B subtype51.
The ERBB2+ (HER2-enriched) subtype is predominantly characterized by high
expression of ERBB2, along with a cluster of several other genes of the ERBB2 amplicon
on chromosome 17q22.24, including the gene for growth factor receptor-bound protein 7
(GRB7)50,51. Tumors of the HER2-enriched subtype also showed low levels of ER
expression and of almost all other genes associated with ER expression, making the
HER2-enriched subtype more closely related to the basal-like subtype than to the luminal
ones. Tumors that cluster into the normal-like group characteristically express high levels
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of genes typical for adipose cells, nonepithelial cells, and basal cells. Expression of
luminal epithelial genes is very low in this subtype. Tumors of the basal-like subtype
show high expression of genes characteristic of basal breast epithelial cells. Specifically,
basal-lineage markers such as keratin 5, keratin 17, integrin beta 4 (ITGB4), and laminin
showed to be enriched in this subtype50,51. ER expression and genes that are typically
within the ER gene expression cluster are absent or expressed at low levels in the basallike subtype. Gene expression typical for the HER2-enriched subtype is also largely
lacking in basal-like tumors. Clinically, the basal-like and HER2-enriched subtypes have
been correlated with the poorest overall and relapse-free survival, while patients with
luminal A tumors are predicted to have the most favorable outcome51. The luminal B
subtype correlates with poorer clinical outcome than luminal A but better than the
remaining subtypes.
Subsequent studies were conducted to explore the full extent of breast tumor
heterogeneity and, in 2007, an additional mammary tumor subtype was discovered by
Herschkowitz et al.53, which was named the claudin-low subtype. They reported this new
subtype to be present in both mouse and human mammary tumor samples and
demonstrated that the tumors of both species showed significant overlap in molecular
features. The mouse tumors that fell into this subtype showed extensive spindle-shape
cell characteristics, and a closer look at the corresponding human samples determined
that the claudin-low subtype is characterized by the low expression of genes encoding for
tight junctions and cell-cell adhesion proteins, including Claudins 3, 4, 7, Occludin, and
E- cadherin. More detailed characterization of this subtype indicated that the majority of
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these tumors are clinically triple-negative breast cancers and are distinct from the basallike TNBCs54.
Significant histopathological diversity and variation in treatment response among
TNBCs motivated Lehmann et al.55 to take a closer look at this clinical subtype. Because
TNBCs were typically analyzed among hormone receptor- and HER2-positive breast
cancers, they largely displayed as a homogenous group due to large transcriptional
differences with these other two clinical subtypes, which likely masked some of the
heterogeneity present in TNBCs. One unfavorable outcome of this clustering approach
was that the vast majority of TNBCs were consequently considered to display basal-like
gene expression56. However, gene expression analysis independent of other clinical
subtypes uncovered that TNBCs display substantial heterogeneity in gene expression
patterns and cluster into six distinct and stable groups55. The six TNBC molecular
subtypes are comprised of two basal-like (BL1 and BL2), an immunomodulatory (IM), a
mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal AR (LAR) subtype.
While almost 50% of all TNBCs were part of the basal-like molecular subtype, the
remaining tumors belonged to other intrinsic subtypes. The majority of tumors that fall
into the M and MSL subtype form the second largest subset of TNBCs and share a
substantial amount of gene expression features that correlate with the claudin-low
subtype. In fact, approximately 30% of all TNBCs cluster to the claudin-low subtype57.
In principle, molecular subtyping of breast cancers can be pushed to the extreme
where only a few tumors make up a subtype. However, the purpose of subtyping based
on gene expression is to identify tumors with biologically relevant similarities without
constructing a subtype so broad that valuable information is lost. As expected, the clinical
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subtyping based on the three markers (i.e., ER, PR, and HER2) is limited and only
reveals a small portion of intertumoral heterogeneity. In fact, Prat and Perou57 have
provided evidence that the classical histopathological markers used in the clinic for tumor
classification (i.e., ER, PR, HER2) do not fully recapitulate the intrinsic subtypes. The
clinical TNBC subtype, for example, is comprised of all intrinsic subtypes where 49% of
triple-negative tumors were basal-like, 30% claudin-low, 9% HER2-enriched, 6%
luminal B, 5% luminal A, and 1% normal-like. Conversely, only 83% of basal-like and
71% of claudin-low breast cancers fall into the clinical TNBC subtype, despite often
being used interchangeably. Not only does this suggest that classical clinical subtyping
by itself is not perfectly reflective of the true breast cancer heterogeneity, it may also
indicate that intrinsic tumor features contribute to some of the variability in treatment
response. In summary, molecular profiling of breast tumors based on gene expression
patterns has advanced our understanding of tumor heterogeneity beyond current clinical
classification and led to the widespread acceptance of six main intrinsic molecular
subtypes: (1) luminal A, (2) luminal B, (3) HER2-enriched, (4) normal-like, (5) basallike, and (6) claudin-low.

1.4 The origin of tumor heterogeneity and the cells-of-origin of different breast
cancer subtypes
Subtyping based on molecular profiles has revealed extensive heterogeneity among breast
tumors. The causes for this heterogeneity are not yet fully understood, but several lines of
investigations suggest that it is multifactorial58,59. Three main factors that are thought to
contribute to the diversity of breast neoplasms are: (1) differences in the cell-of-origin,
(2) genetic and epigenetic alterations, and (3) changes in the microenvironment.
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To understand the intratumoral heterogeneity of breast cancer, it is essential to be
aware of the cellular heterogeneity that is already present in the normal mouse and human
mammary gland. During embryonic development the ectoderm gives rise to the
mammary line that forms into placodes and eventually develops into a rudimentary ductal
structure of the mammary gland that is present at birth60. Postnatal development of the
mammary gland is regulated by hormones that control pubertal growth, pregnancy,
lactation, and involution. At the onset of puberty, the rudimental mammary gland
expands into the mammary fat pad and develops into a more extensive ductal tree
accompanied by alveoli formation during pregnancy. The lactation stage, during which
alveoli secrete milk, is followed by a mammary gland remodeling process called
involution that restores the mammary gland to its pre-pregnancy state upon weaning of
the offspring. All these stages involve numerous signaling pathways and distinct,
specialized mammary gland subpopulations whose features are often reflected in the
intrinsic subtypes of mammary cancers. Two main cell lineages constitute the mammary
gland epithelium throughout the ductal and lobular system in a bi-layered manner:
luminal cells that surround a central lumen, and basal/myoepithelial cells that are located
between the luminal cells and the basement membrane59 (Figure 1.1). Several reports
suggest that there is substantial heterogeneity within these two lineages, but the cellular
hierarchy is yet to be fully determined. It is thought that at the top of the hierarchy are
mammary stem cells (MaSCs) that predominantly reside within the basal cell population
and are capable of giving rise to both basal and luminal cell lineages in the adult
mammary gland59,61,62. Two schools of thought have emerged in the debate on the
existence of MaSCs/bipotent-progenitor cells in the adult mammary gland. While some
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Figure 1.1 Basic anatomical features of the human female breast and a cross-section
of a mammary duct
Breast anterior view (left) shows the basic anatomy of a human female breast with ducts
leading to the nipple. Alveoli are the milk producing structures during pregnancy. Ducts
and alveoli are surrounded by adipose tissue. Ductal cross-section (right) showing the
differentiated luminal, differentiated myoepithelial, basal progenitor, luminal progenitor,
and the mammary stem cells. Duct is surrounded by the basement membrane and inside
is a lumen. Figure was created with Biorender.com.
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colleagues believe that the luminal and basal lineages emerge from separate unipotent
progenitors; others are convinced that bipotent progenitors give rise to both lineages59.
Through intricate lineage tracing in mouse models, Rios et al.63 provided convincing
evidence that both – bipotent MaSCs and distinct long-lived progenitor cells – exist in the
mammary gland. Furthermore, they provide evidence that bipotent MaSCs reside in the
basal cell subpopulation and fulfill important biological functions in postnatal mammary
gland development. Although evidence for the existence of MaSCs is abundant, there is
much controversy about molecular markers defining this cell population, which suggests
that the MaSC population itself may display some degree of heterogeneity59. Single cell
markers such as Lgr5, Procr, and selected ALDH family members have been shown to
enrich for bipotent MaSCs64-66, but none of these markers is a perfect predictor for in vivo
stem cell function. Numerous other markers have been used to label MaSCs, including
CD44high CD24low 67, CD10positive 68, EpCAMpositive MUC1negative 69, EpCAMlow CD49fpositive
70

, and CD24positive CD29high CD49fhigh 61,62, but whether these MaSC markers identify the

same cell population is still largely unknown. Additionally, Roy et al.71 have
demonstrated that normal human breast cells can exhibit extensive lineage plasticity,
potentially explaining some of the inconsistency in MaSC markers. More recent single
cell-based gene expression studies by Chen et al. 72 confirm that the adult mammary
epithelium contains bi-potent MaSCs and that these cells are characterized by
overexpression of the transcription factors ENO1 and YBX1 and also correlated with
high expression of CD44 and ITGA6 (CD49f). Most remarkably, the authors show that,
while most bipotent MaSCs reside within the basal cell cluster, a smaller fraction
assembles between the immature luminal and basal clusters, further supporting that
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MaSCs are a somewhat heterogenous population in itself. Overall, these studies suggest
that the adult mammary gland contains MaSCs that can give rise to the luminal and
basal/myoepithelial lineages. For completeness, it should be mentioned that the
mammary microenvironment (niche) likely plays a significant role in stem cell biology in
the mammary gland. For example, Boulanger et al.73 have demonstrated that cells from
adult seminiferous tubules were able to adopt mammary epithelial progenitor cell
properties, including self-renewal and the production of cell progeny, when transplanted
into the mammary glands. These cellular descendants were shown to subsequently
differentiate into functional mammary epithelial cells. Further studies confirmed that
other mammary epithelial lineages (the “niche”) can dictate the fate of non-mammarygland pluripotent stem cells, which adopt the ability to give rise to a fully functional
mammary gland74. This even holds true when human totipotent stem cells are
transplanted into the mouse mammary gland75. These studies suggest that the initial cell
identity of the MaSCs might not be an important factor and that stem cells might be
substantially impacted by the mammary niche. The existence of the other cell states of
the mammary gland is less controversial and each one has been fairly well characterized.
Mature luminal cells occur as two major populations based on their localization in the
mammary gland compartment; ductal luminal cells, which line the mammary ducts, and
alveolar luminal cells, which are the milk-secreting cells residing in the lobules during
pregnancy and lactation. Generally, the luminal lineage is marked by luminal-specific
lineage markers keratin 8/18/19 and enrichment for ER and/or PR expression76. However,
estrogen receptor expression may depend on the cell population of the mature luminal
lineage as luminal alveolar cells are generally considered to be ER-negative, while
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mature ductal cells can be positive or negative for ER77. Another marker that shows
strong luminal-lineage specificity is the GATA binding protein 3 (GATA3), which is a
critical regulator of luminal differentiation78. Lack of GATA3 severely interferes with
ductal elongation and branching morphogenesis as well as lobule formation during
pregnancy and lactation. GATA3 is expressed at higher levels in more differentiated
luminal cells and is completely absent in basal cells. Within the cellular hierarchy, the
mature luminal cells and the bipotent MaSC are connected through another luminallineage cell known as the luminal progenitor. This progenitor is thought to give rise to
mature ductal and alveolar cells and can be discriminated from the differentiated luminal
population through several markers including CD61 (Itgb3)78, CD49b79, CD1479,80, and cKit81. Other intermediate cells have been proposed to exist that connect the luminal
progenitor cell to its two mature descendant population: (1) a ductal progenitor that has
many characteristics of the common luminal progenitor but expresses Sca1, a marker for
cells that express high levels of luminal differentiation proteins (i.e., ER, K8, and
K18)59,79, and (2) an early and late alveolar progenitor, which shares similar markers with
the ductal progenitor but is negative for ER and Sca159. A population of self-renewing
alveolar progenitors was identified by Wagner et al.82 and belongs to a subset of cells that
survive the involution process and give rise to alveolar cells in subsequent pregnancies.
These parity-induced mammary epithelial cells (PI-MECs) have been subsequently
reported to be ER-negative and reside exclusively in the luminal ductal compartment83.
Moreover, upon pregnancy and lactation these cells contribute exclusively to the
secretory ER-negative cells of the alveoli, but not to the hormone sensing ER-positive
cells or the myoepithelial lineage. The basal/myoepithelial is the other cell lineage that is
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thought to arise from the bipotent MaSC, where the myoepithelial cell is considered the
terminally differentiated state of this basal lineage. Mature myoepithelial cells play an
essential role during lactation where they contract upon oxytocin stimulation to cause
milk ejection by the mammary gland84. As with the luminal lineage, the mature
myoepithelial cell is presumably connected to the bipotent MaSC through basal
progenitor intermediates. Well established immune-markers for this lineage are
Cytokeratin 5 and 14 (CK5 and CK14)76. A combination of cell surface markers,
CD49fhigh CD29high CD24positive/moderate Sca1low, has also been used to identify the broader
basal lineage61,62,79. Generally, a few cell surface markers are used in combination to
separate the luminal and basal populations from each other. EpCAMpositive CD49fnegative
cells are considered to be mature luminal cells, EpCAMpositive CD49fpositive cells are
luminal progenitors, and basal/myoepithelial cells are defined by the EpCAMnegative
CD49fpositive phenotype85. Other cell surface markers such as CD44 and CD24 have been
used to classify luminal epithelial cells with hormone signaling gene expression
signatures (CD24+) and cells that resemble progenitor cells that express motilityassociated genes (CD44+)86.
As mentioned earlier, the normal mammary gland is comprised of a wide variety
of different cells, many of which show strong similarities to the intrinsic subtypes of
malignant breast cancers50. Traditionally it was theorized that MaSCs play a key role in
breast cancer initiation as they presumably possess a lower threshold for oncogenic
transformation than progenitor cells or differentiated cells. The reduced potential of
progenitor cells to continuously self-renew and the reduction in proliferation potential of
differentiated mammary epithelial cells were seen as substantial hurdles for cancer
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initiation and progression87. Although related, the concept of the cell-of-origin of breast
cancer is distinct from the cancer stem cell model. While the cancer stem cell concept
focuses on a small population of tumor-initiating cells that maintain tumorigenesis and
seed metastases, the notion of the cell-of-origin focuses on the original normal cell type
of the breast that ultimately gives rise to macroscopic tumors. Some of the main intrinsic
molecular subtypes such as luminal A, luminal B, and basal-like are named based on their
molecular (transcriptomic) similarities to corresponding normal breast cells (i.e., luminal
or basal). However, the true cell-of-origin might not be molecularly reflected in the final
intrinsic tumor subtype. Lim et al.70, for example, have reported that basal-like, BRCA1associated breast cancers can arise from luminal epithelial progenitor cells. A subsequent
study by Molyneux et al.88 compared the role of BRCA1 loss in basal cells and βlactoglobulin-expressing luminal cells and demonstrated that basal-like tumors that
resemble the human disease developed only from luminal epithelial progenitor cells,
while mammary tumors originating from basal cells formed basal-like tumors that did not
resemble the human disease, suggesting that that luminal progenitor cells are the more
likely precursor for basal-like BRCA1-associated breast cancers. This is contrary to the
previously held belief that these breast cancers originate from MaSCs based on the
premise of shared molecular features89. Co-deletion of the p53 gene and BRCA1 in the
CK14-positive basal cell compartment confirmed the notion that basal-like mammary
cancers arise from basal cells90, but these mammary tumors do not resemble BRCA1associated human cancers88. Interestingly, the cell(s)-of-origin of tumors that exhibit a
luminal A or luminal B subtype are largely unexplored, possibly because it is assumed
that this subtype, most likely, originates from luminal progenitors or mature luminal cells
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due to shared molecular characteristics59,87. Luminal A and luminal B tumors are also
typically hormone driven tumors and it may seem unlikely that lineages or cell
populations that do not express ER and/or PR give rise to hormone dependent tumors. In
sharp contrast to this notion, Van Keymeulen et al.91 demonstrated that basal mammary
cells can give rise to ER- and PR-positive luminal-like tumors in response to expression
of oncogenic PIK3CA. This establishes that non-luminal cells can, at least in principle,
give rise to hormone receptor positive luminal breast cancers. The cell-of-origin of
tumors that belong to the HER2-enriched subtype is not definitively established. Based
on hormone receptor status, HER-2 enriched tumors show significant heterogeneity, but
molecularly, they are defined by a common set of HER2-regulated genes50,57. This
observation may imply that the subtype of these tumors is driven by a shared oncogenic
signaling pathway rather than a common cell-of-origin. However, mouse model-based
evidence for a potential cell-of-origin points towards parity-induced mammary epithelial
cells (PI-MECs)92. These cells undergo significant numeric expansion during pregnancy
and lactation contributing to the luminal alveolar cell population and a limited number of
these cells subsequently survive mammary gland involution82,83. Indeed, ablation of PIMECs reduces the frequency of tumor onset in MMTV-neu mice92. On the molecular
level, however, the MMTV-neu mouse model does not closely represent the human
HER2-enriched subtype93.
Based on current knowledge, the cell-of-origin contributes considerably to the
heterogeneity among breast tumors. The cell-of-origin alone, however, is unlikely to
account for the full extent of diversity and likely cooperates with lineage-enriched
oncogenic drivers. Genomic analyses confirmed that luminal A and luminal B tumors
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exhibit distinct mutational profiles that include mutations in key regulators of luminal
differentiation such as PI3K, MAP3K1, GATA3, FOXA1 and TBX394. Genomic features
characteristic of basal-like tumors are an increase in somatic mutations in non-coding
regions, a lower frequency of gene mutations, and a higher degree of genome instability.
Notably, over 80% of basal-like tumors exhibit mutations in TP53, while other gene
mutations occur at frequencies independent of this subtype94.
1.5 The origin and oncogenic drivers of claudin-low mammary cancer
As described earlier, the claudin-low subtype constitutes a significant portion of TNBCs
and exhibits features of mesenchymal cells57. The claudin-low subtype was initially
characterized by low expression of genes that encode for tight junction and cell adhesion
proteins (i.e., claudin 3, 4 and 7, and E-cadherin)53. Subsequent studies on CD44+/CD24/low

tumor initiating cells (TICs) in human breast tumors indicated that the gene

expression signature of TICs exhibits a high similarity with the claudin-low subtype95,96.
Moreover, neoadjuvant chemotherapy or hormone therapy enriched for this TIC/claudinlow gene signature in posttreatment residual cancers95. In 2010, Prat et al.54 characterized
the claudin-low subtype more thoroughly and identified several unique phenotypic and
molecular features of claudin-low breast cancers that distinguish them from other
subtypes. Low expression of HER2 and luminal markers (i.e., ER, PR, GATA3, and
CK18) as well as the previously identified luminal gene cluster confirmed that claudinlow cancers are predominantly non-luminal TNBCs. An important discriminating factor
between basal-like and claudin-low tumors is that the latter show significantly lower
expression of proliferation genes. Most remarkably, the claudin-low subtype shows
strong enrichment of epithelial-to-mesenchymal transition markers, immune response
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genes, and cancer stem cell-like features. Tumors of this subtype also exhibited low gene
expression of differentiated luminal cell surface markers (e.g., CD24, EpCAM and
MUC1), and very high expression of CD44 and CD49f. Both, CD44+/CD24-/low and
CD49f+/EpCAM-/low cells, have been previously associated with TICs and MaSCs70,97. A
gene-expression-based differentiation predictor confirmed that claudin-low breast cancers
are the least differentiated subtype and resemble a MaSC profile. In addition, high
expression levels of the epithelial-to-mesenchymal transition (EMT) markers, including
SNAI1, SNAI2, TWIST1, TWIST2, ZEB1 and ZEB2, was commonly observed in
claudin-low mammary tumors. Generally, these tumors show strong mesenchymal
features as confirmed by vimentin staining. Thus, stem cell and EMT features are two of
the defining characteristics of claudin-low mammary cancer. Both of these features have
been previously linked to one another98,99, and indeed, the expression of EMT-inducing
transcription factors or the repression of E-cadherin were shown to increase the
abundance of mammary stem cells98,100. As many of the EMT-inducing transcription
factors repress E-cadherin (including SNAI1 and SNAI2), an active EMT signaling
program seems to be essential for the claudin-low subtype101,102. Clinically, claudin-low
breast cancer is associated with young age of tumor onset, higher tumor grade, larger
tumor size and extensive lymphocytic infiltrate103. The relapse free survival and the
overall survival of patients with claudin-low breast cancer is comparable with other poor
outcome subtypes such as basal-like and HER2-enriched54,103.
Despite a fairly detailed analysis of the phenotypic, molecular, and clinical
features of claudin-low breast cancers, little is known about the cell(s)-of-origin and
oncogenic drivers that give rise to this subtype. Because the claudin-low subtype reflects
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many molecular features of the mammary stem cell (MaSC), it was previously assumed
that the cell-of-origin of this subtype is the MaSC59,87. The idea behind this assumption is
that the cell-of-origin clonally expands during the early stages of neoplasia and
consequently impacts further neoplastic progression and tumor biology87. Moreover, the
normal precursor cell is believed to epigenetically pass on characteristics to the malignant
tumor cell and its descendants, with the result that the advanced mammary tumor reflects
many molecular aspects of the cell-of-origin. To infer the cell-of-origin of a mammary
cancer subtype based on molecular similarities is merely correlative and does not prove
that the MaSC is the normal precursor for claudin-low breast cancers. The gold standard
to detect the cell-of-origin is cell lineage tracing, but the lack of suitable in vivo models
has, thus far, prevented the study of claudin-low tumor initiation and progression. Two
commonly used models for claudin-low research are the T11 model and the DMBAinduced model. T11 is an orthotopic syngeneic transplant model (transplantable cell line)
that originated from a mouse with a germline homozygous deletion of p53104. Because
T11 is an established cancer cell line and does not spontaneously develop from the
mammary gland it is not suitable for cell lineage tracing studies during tumor initiation.
A subset of mice from the 7,12-dimethylbenzanthracene (DMBA)-induced model have
also shown to give rise to claudin-low mammary tumors that closely resemble the human
claudin-low subtype105. This model is based on chemical induction of mammary tumors
and inconsistently gives rise to claudin-low mammary cancers. These neoplasms carry a
wide array of tumor initiating mutations, which makes this model unsuitable for
controlled tumor initiation and lineage tracing studies.
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Little is also known about oncogenic drivers of the claudin-low subtype. An
examination of 50 breast cancer cell lines has revealed that 7 out of 10 bona fide basallike breast cancer cell lines belong to the claudin-low subtype57,106. MDA-MB-231, the
most commonly used human TNBC cell line to study mechanisms of breast cancer
invasion and metastasis, was among these 7 claudin-low cell lines. Common
characteristics of many human TNBCs, including claudin-low tumors, are mutations in
TP53 (Trp53 in the mouse) and members of the PI3K/AKT pathway. This subtype also
exhibits a hyperactivation of the RAS/MAPK signaling pathway due to amplifications or
gain-of-function mutations in KRAS and BRAF as well as loss of NF194,107,108. Genomic
abnormalities in this pathway are further enriched in residual breast cancers following
neoadjuvant chemotherapy109, which potentially coincides with the previously mentioned
enrichment of the TIC/claudin-low gene signature in posttreatment residual cancers95.
These findings might explain why RAS/MAPK pathway mutations are present in
commonly used breast cancer cell lines that were derived from pleural effusions.
It is well established that active RAS affects multiple effector pathways known to
play a role in oncogenesis and cancer progression. The RAS protein is a small
membrane-localized GTPase that is activated by a number of upstream cellular receptors
[i.e., receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs)] and some
integrin family members110. In the wildtype form, inactive GDP-bound RAS is converted
to the active GTP-bound state by the RAS-guanine exchange factor (RAS-GEF) SOS1
upon upstream signaling. Subsequent inactivation of RAS occurs through RAS-GTPase
activity which is catalyzed by RAS-GAP proteins. In cancer, RAS and RAS-activityregulating genes are frequently mutated, which leads to RAS hyperactivation independent
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of upstream signaling. For instance, loss of the RAS-GTPase activating enzyme (RASGAP) neurofibromin 1 (NF1) and mutations in its gene are observed in more than 40% of
all basal-like breast cancers and correlate with hyperactivation of RAS108. While only
~4% of breast cancers show mutations in RAS genes (COSMIC), many RAS and RAS
effector pathway components are amplified in TNBCs, including PIK3CA (49%), KRAS
(32%), BRAF (30%) and EGFR (23%)94. Moreover, some TNBCs cancers also show
amplifications in RTKs (i.e, FGFR1, FGFR2, IGFR1, KIT, MET and PDGFRA).
Hyperactive RAS impacts a variety of pathways that promote oncogenic transcription,
cell cycle progression, cellular survival, cell growth and metabolism, as well as cell
motility and migration111. A few of the central RAS effector pathways are (1) the
mitogen-activated protein kinase (MAPK) pathway, (2) the PI3K-AKT signaling
network, (3) the TIAM1signaling cascade, and (4) the RAS-Like (RAL) signaling
pathway112. The MAPK pathway comprises the RAF-MEK-ERK signaling axis and
promotes cell proliferation through transcriptional activation of genes such as FOS, JUN,
and MYC113. The PI3K-AKT signaling network supports oncogenic transcription, cell
survival, and cell growth through NF-κB signaling, inhibition of the pro-apoptotic
enzyme BAD, and mTOR signaling, respectively111. TIAM1 activation promotes cancer
cell motility and migration through the Rac-Rho and Rac-PAK axes, and RAL-GEF
signaling supports anchorage-independent proliferation and survival of neoplastic
cells114.
Interestingly, five of the seven claudin-low breast cancer cell lines that were
identified by Prat et al.106 have RAS-activating mutations or mutations in components of
RAS effector pathways. Three of the seven cell lines have known hotspot mutations in
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KRAS or HRAS (COSMIC). In addition to an oncogenic KRAS mutation115, the claudinlow cell line MDA-MB-231also carries mutations in BRAF116 and NF1107, suggesting that
high levels of RAS/MAP kinase signaling might play critical roles in the cellular
plasticity and metastatic characteristics of claudin-low breast cancer cells.

1.6 Conclusion and dissertation hypothesis
Annually, more than 620,000 women die worldwide as a result of breast cancer117. In the
US alone, it is estimated that 276,480 women will be diagnosed and 42,170 will die of
breast cancer in 2020 (statistics obtained from SEER). Additionally, more than 3.5
million women in the US currently live with breast cancer and more than 1 in 8 women
will be diagnosed with this disease throughout their lifetime (SEER). As the second
leading cause of cancer-related deaths in women, breast cancer remains a challenging
disease to treat118. The extensive intratumoral and intertumoral heterogeneity presents a
significant obstacle. However, classical histopathological markers currently used in the
clinic for tumor classification (i.e., ER, PR, and HER2) are not fully recapitulating the
full variety of intrinsic subtypes. This clinical classification is useful for subtypes that can
be treated with targeted therapies against oncogenic drivers, namely ER/PR and HER2.
However, the benefits of targeted therapy have not been relevant for TNBC patients
largely due to clinically unaccounted heterogeneity. Patients with metastatic TNBC
display dismal clinical outcome, with a 5-year relative survival rate of only 11.5%
(SEER), and only a small subset of tumors (BRCA-associated) can be treated with
olaparib, a PARP inhibitor . The standard therapy for TNBC remains cytotoxic
chemotherapy119, which represents a broad-spectrum approach that does not take into
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account any subtype-specific susceptibilities. Prat et al.57 and Lehmann et al.55 have
reported that the clinical TNBC subtype is heterogeneous, with the basal-like and
claudin-low intrinsic subtypes contributing to most cases. The basal-like subtype and
TNBC have often been displayed as synonymous in the scientific literature, neglecting
more than 50% of the other intrinsic molecular subtypes that make up TNBCs.
Accounting for 30% of all TNBCs, the claudin-low subtype is the second largest group
and is highly enriched for characteristics that have been considered as clinically
unfavorable such as a high level of stem cell and EMT features, poor cellular
differentiation, and the increased presence of intra-tumoral, immune-suppressive
lymphocytes54,103,120. However, despite poor clinical features, little is known about the
cell(s)-of-origin or oncogenic drivers that give rise to claudin-low TNBCs. Given the
success of cancer prevention and targeted therapies in a subset of breast cancer patients
(i.e., hormone receptor-positive, and HER2-positive cancers), it is clear that if claudinlow breast cancers are to be successfully treated it will be essential to identify common
oncogenic drivers of this subtype so that they can be targeted. Similarly, understanding
the cell-of-origin of the claudin-low subtype and the role that cellular plasticity plays in
its tumor initiation and maintenance may aid in preventing the development, metastatic
dissemination, and recurrence of this aggressive breast cancer subtype. Interestingly, a
high proportion of human claudin-low triple-negative breast cancer cell lines show bona
fide oncogenic alterations in RAS and its effector pathways, including the most
frequently used breast cancer model to study invasion and metastasis – the cell line
MDA-MB-231. Thus, high levels of RAS signaling might significantly contribute to the
cellular plasticity and metastatic characteristics of claudin-low breast cancer cells.
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Based on previously published articles and preliminary observations from our
team, we hypothesized that the hyperactivation of the RAS signaling pathway in the
mammary epithelium can lead to the development of metastatic triple-negative mammary
cancers. Moreover, we propose that this signaling pathway controls the degree of cellular
plasticity and promotes epithelial-mesenchymal transition that might be related to the
genesis of a claudin-low molecular tumor subtype. To address this hypothesis, we had to
first generate new genetically engineered models that express oncogenic RAS in a
constitutive and differentiation-independent manner to assess the full extent of cellular
plasticity driven by this pivotal signaling pathway.
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Chapter 2: Materials and Methods
2.1 Genetically modified mouse strains
The mouse strains utilized in this study are summarized below (Table 2.1). Our team
constructed the EF1-LSL-tTA knockin, the MMTV-tTA, and the WAP-Cre transgenic
lines. At the time of submission, the MMTV-Flp strain is unpublished and a more
detailed description of the generation and analysis will follow. Dr. Miyazaki (Osaka
University) kindly provided the CAG-LSL-GFP reporter strain. All other mouse strains
were obtained from The Jackson Laboratory or the NCI Mouse Repository (see Table
2.1). To generate the Trp53R172H mutant allele described in this study, the LSLTrp53R172H/+ allele was passed through the germline of line A MMTV-Cre [Tg(MMTVcre)1Mam] transgenic females. The transgenes were carried in the FVB/N genetic
background. To move the FSF-KrasG12D, Trp53R172H/+, and Rosa26CAG-FSF-GFP alleles
into an FVB/N background, these alleles were backcrossed up to seven times with
FVB/N wildtype mice. The use of rodents and the animal study protocols for this work
were approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of Nebraska Medical Center and Wayne State University. The animal work
presented here was conducted in adherence to the recommendations provided in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health
and monitored by Comparative Medicine at UNMC and IACUC at Wayne State
University.
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Table 2.1 Mouse models utilized in this study
Mouse Strain

Allele Symbol

Source

EF1-LSL-tTA

Eef1a1tm1(tTA)Kuw

Wagner

MMTV-tTA
WAP-Cre
MMTV-Flp
CAG-LSL-GFP

Tg(MMTV-tTA)25754Kuw
Tg(Wap-cre)11738Mam
NA
Tg(CAG-cat,-EGFP)39Miya

TetO-KrasG12D

Tg(tetO-Kras2)12Hev/J

TetO-H2B-GFP

Tg(tetO-HIST1H2BJ/GFP)47Efu/J

Rosa26CAG-FSF-GFP

Gt(ROSA)26Sortm1.2(CAGEGFP)Fsh

FSF-KrasG12D

B6(Cg)-Krastm5Tyj/J

LSL-Trp53R172H/+

Trp53tm2Tyj

Wagner
Wagner
Wagner
Miyazaki
Jackson Laboratory
(#004375)
Jackson Laboratory
(#005104)
Jackson Laboratory
(#32038)
Jackson Laboratory
(#023590)
NCI Mouse
Repository

Reference
Sakamoto and
Rädler et al.121
Zhang et al.122
Wagner et al.123
Unpublished
Kawamoto et al.124
Fisher et al.125
Tumbar et al.126
Sousa et al.127
Young et al.128
Olive et al.129

2.2 DNA extraction from mouse tissue
Tissue for DNA extraction was obtained by performing a tail biopsy cutting off <0.25cm
of the tail end before the mouse had reached 3 weeks of age. Mammary tumor tissue was
obtained by euthanizing the mouse, followed by excision of the mammary tumor and
isolation of a representative tumor fragment no larger than 8mm3. Tissue samples were
digested overnight at 56°C in 500µL of digestion buffer and 20µL of 10 mg/ml
proteinase K (PK). The digestion buffer was composed of 1% SDS, 50nM Tris/HCl pH8,
100nM NaCl, and 50 mM EDTA. Subsequent DNA extraction occurred automated with
the AutoGenprep2000 and consistently yielded high quality and quantity of genomic
DNA. The reagents used for this automated DNA extraction are proprietary to AutoGen
and contain phenol, ethanol, I-butanol (9%), iso amyl alcohol (0.01%), and 33
isopropanol (40%). When manual DNA extraction was required, the digested tails were
processed as follows: digested tails were spun down for 20min at 13,000 RPM in a
tabletop centrifuge at room temperature and the resulting supernatant (Digestion buffer
+PK) was transferred into a fresh new tube. Phenol (Invitrogen, #15513-047) was added
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at a 1:1 ratio, the solution was inverted a few times and centrifuged for another 20min at
13,000 RPM. The DNA-containing top layer was transferred into a fresh tube,
resuspended in 600µL of chloroform (Fisher, #BP1145-1) and mixed by inverting,
followed by centrifugation at 13,000 RPM for 20min. The resulting top layer was
transferred into a new tube and mixed with 1mL of 100% ethanol (Sigma-Aldrich,
#E7023-1L), which leads to the precipitation of the DNA. Centrifugation at 13,000 RPM
for 10min resulted in a DNA pellet at the bottom of the tube. Supernatant was poured off
and the DNA pellet was re-suspended in 80-100µL of Tris-EDTA (TE) (Fischer
Bioreagents, #BP2473-1) after 15min of letting the DNA pellet dry. DNA concentrations
and purity were assessed using a NanoDrop 2000 (Fisher Scientific, # ND2000).

2.3 PCR-based genotyping of genomic DNA
For genotyping of mice, extracted genomic tail DNA was analyzed using polymerase
chain reaction (PCR) assays to confirm that the mice carried the desired transgenes. The
procedure to genotype extracted genomic tumor DNA is identical. A single PCR unit
contained the following constituents: 32.5µL of UltraPure Distilled Water (Invitrogen,
#10977-023), 10µL of 5x PCR buffer (Promega, #M890A), 3µL of 25mM MgCl2
(Promega, #A351H), 1µL of 10mM dNTPs (Invitrogen, #18427088), 0.5µL of each
100pM primer (forward and reverse, see Table 2.2), 0.5 µL of 5U/µL Taq DNA
polymerase (Promega, #M829B), and 1 µL of genomic template DNA for a total of
50µL. A T3 Thermocycler (Biometra) was used to perform the PCR and all primers were
suitable to use under the same PCR conditions:
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Step 1: Heat samples to 96°C (3min)
Step 2: 96°C for 1min (denaturation)
Step 3: 60°C for 1min (annealing)
Step 4: 72°C for 1min (extension)
(Step 2-4 are repeated 32x)
Step 5: 72°C for 5min
Step 6: 4°C (¥)
PCR products were mixed with 5µL of 10x loading dye and 20µL of this mixture were
loaded and run on a 1-2% agarose gel. This gel is made by dissolving agarose (Thermo
Scientific, #J32802-A1) in 1x Tris-34 Acetate-EDTA (TAE) buffer (Fisher Scientific,
#BP1332-20) and 1µL/ml of the total volume of ethidium bromide (Ameresco, #X32810ML). The gel was visualized using UV-based imaging with the UVP GelStudio PLUS
(Analytic Jena).
Table 2.2 PCR primers used for genotyping
Transgene/Allele

Primer #

Sequence (5’ - 3’)

bp

EF1-LSL-tTA

2453
2454
2127
599
132
580
2546
2128
2004
2211
2366
2367
811
2031
2729
2730
2731
2528
2529
2530
2598
2599

CGA CTG TGC CTT CTA GTT GCC
AAG AAT GAC TTC CAG CGC CAG GC
AGT GAT AGA GCT CTT GCC TAG C
GCC AAT ACA GTG TAG GCT GC
TAG AGC TGT GCC AGC CTC TTC
CAT CAC TCG TTG CAT CGA CC
CCT GGA ACG GCA TCA TCA GC
CTC CCA TTC ATC AGT TCC ATA GG
GGC TCT AGA GCC TCT GCT AAC C
GCC ATT GGG ATA TAT CAA CGG TG
GCC TGC GAC GGC GGC ATC TGC
GGG AAT AAG TGT GAT TTG CCT
CCG TCC AGC TCG ACC AGG ATG G
TAC AAC AAG CGC TCG ACC ATC AC
CCC AAA GTC GCT CTG AGT TGT TAT C

315

MMTV-tTA
WAP-Cre
MMTV-Flp
CAG-LSL-GFP
TetO-KrasG12D
TetO-H2B-GFP
Rosa26CAG-FSF-GFP

FSF-KrasG12D

Trp53R172H

GAA GGA GCG GGA GAA ATG GAT ATG
CCA GGC GGG CCA TTT ACC GTA AG
CAC CAG CTT CGG CTT CCT ATT
AGC TAA TGG CTC TCA AAG GAA TGT A
GCG AAG AGT TTG TCC TCA ACC
AGC CTG CCT AGC TTC CTC AGG
CTT GGA GAC ATA GCC ACA CTG

364
210
275
~270
320
447
550 (wt)
350 (mu)
270 (wt)
350 (mu)
290 (wt)
330 (mu)
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2.4 EF1-tTA targeting vector construction
The pEF1 targeting vector was previously described by Klinakis et al.130 and kindly
provided to us by them. This vector contains the genomic sequence of Eef1a1 (EF1) with
812bp and 3,606bp homology arms that are separated by a multi-cloning site (MCS)
carrying the Pac1, Pme1, and Asc1 restriction sites that allow for the insertion of the
desired cassette between the two homology arms. We aimed at constructing a directional
insertion cassette into this MCS that contains the tetracycline transactivator (tTA) gene
that, in the absence of Cre-recombinase is preceded by a transcriptional Stop sequence to
prevent the expression of tTA. To accomplish this, we utilized the directional pSA-LoxPpA cassette and isolated the tTA coding sequence from the CMV-tTA plasmid (kindly
provided by Lothar Hennighausen, NIH) as blunt fragment (EcoRI/BamHI) and inserted
it into the MCS (EcoRI/NotI blunt) of the pSA-LoxP-pA cassette, which is located
downstream of the 3′ loxP site and precedes the 5′ polyA site from the bovine growth
hormone (bGHpA). The bGHpA functions as transcriptional Stop sequence of the tTA
from the endogenous EF1 locus once the floxed-Neo-polyA fragment is deleted in the
presence of Cre recombinase. Prior to Cre-mediated excision of this sequence, the NeopolyA functions as a neomycin selection marker (Neo, used for ES targeting) and
transcriptional Stop sequence (polyA, used to prevent downstream gene transcription)
that is driven by the endogenous EF1 locus and facilitated by the splice acceptor (SA)
that precedes the 5′ loxP site. The insertion of the tTA resulted in the pSA-LoxP-tTA-pA
cassette which is flanked by Pac1 and Asc1 restriction sites and was used to directionally
insert this cassette into the pEF1 targeting vector to generate the final EF1-loxP-Stop-
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loxP-tTA (EF1-LSL-tTA) targeting vector that was used for subsequent embryonic stem
cell (ESC) gene targeting.
2.5 Embryonic stem cell (ESC) gene targeting and validation
ESC gene targeting. To introduce the EF1-LSL-tTA targeting vector into ESCs, the
vector was linearized, purified, and electroporated into S1B6A embryonic stem (ES) cells
that were derived from a 129 Sv Å~ C57BL/6 F1 embryo. Targeted ESCs were selected
for neomycin resistance using Geneticin (G418, Gibco, #10131-035) and expansion of
individual ESCs was conducted at the Genetically Engineered Mouse Modeling Core
(GEMMC) at The Ohio State University as described previously by Piovan et al.131.
Southern blot to validate correct targeting. Southern blot analysis was performed on ESC
clones to confirm the correct targeting of the LSL-tTA into the endogenous EF1 locus.
15µg of genomic DNA derived from ESCs was digested overnight at 37°C with the
restriction enzyme EcoRV, followed by separation via gel electrophoresis on a 0.7%
agarose gel. The resulting DNA was denatured and transferred onto a GeneScreen Plus
hybridization transfer membrane (Perkin Elmer, #NEF987001PK). A 616 bp 5′ external
probe was isolated and labeled with 32P using the Random Primed DNA Labeling kit
(Roche, # 11004760001). Next, membranes were hybridized overnight at 65°C with the
labeled probe. Subsequently, membranes were washed in 0.1x SSC buffer containing
SDS and were exposed for 48 hours to a KODAK XAR autoradiography film (Perkin
Elmer, #1651454) at −80 °C. Results are described in Chapter 3. Sothern blot was also
used to validate the transmission of the targeted allele through the germline of male
chimeric mice. Subsequently, PCR-based genotyping was used on founder mice and their
offspring. Primers used are found in Table 2.3. Results are described in chapter 3 as well.
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Table 2.3 Primers for validation of correct LSL-tTA targeting into the EF1 locus
Primer #

Sequence (5’ - 3’)

2452
2131
2453
2454
599

CCG CAA TAG TCA CCT CGG GCT T
TTC GGA GCA CAT GTC CGA CG
CGA CTG TGC CTT CTA GTT GCC
AAG AAT GAC TTC CAG CGC CAG GC
GCC AAT ACA GTG TAG GCT GC

2.6 In vivo bioluminescent imaging
The expression of the luciferase reporter in mammary glands of live mice was determined
by bioluminescent imaging with the In Vivo Imaging System 200 (IVIS-200, Xenogen).
The 30 mg/mL (200x) stock luciferin solution was prepared by diluting 1g of D-Luciferin
(Xenogen, #XR-1001) in 33.3 mL of sterile water. The working solution of luciferin was
prepared immediately before use by diluting an appropriate amount of stock luciferin
needed for the experiment with an equal volume of Mg2+/ Ca2+ free 2xPBS (Gibco,
#70011-069) for a final luciferin concentration of 15mg/mL and was kept protected from
light until injected. Five minutes prior to imaging, the mice were injected
intraperitoneally with 150mg/kg of luciferin. Immediately before imaging, mice were
anesthetized by exposing them to a 2.5% Isoflurane (Henry Schein, #1182097) flow rate
using the IVIS-200 supplied XGI-8 gas anesthesia system. Mice were kept anesthetized
during the imaging process by placing their snouts into isoflurane inhalation cones.
Images were obtained at an exposure length from 5 seconds up to 2 minutes.

2.7 Orthotopic cancer cell/ tumor fragment transplantation and doxycycline
treatment of tumor-bearing mice
8 to 12 week-old female wildtype NCrnu/nu mice (The Jackson Laboratory, #002019)
received bilateral orthotopic transplants of mammary tumor fragments or tumor cells into
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the #4 inguinal mammary glands. For this, mice were anesthetized, disinfected and a
ventral Y-shaped skin incision was made. The #4 inguinal mammary glands were
exposed by separating the skin from the peritoneum. Next, mammary tumor fragments of
maximally 1.5mm in diameter derived from transgenic females were transplanted into the
glands by forming a small pocket within the fat pad with very fine point forceps,
followed by the deposition of the fragment into this pocket. For mammary cancer cell
line transplants 2x105 cells were injected with a syringe. The cells were suspended in a
1:1 mix of sterile 1xPBS and growth factor reduced matrigel (Corning, #354263). After
successful transplantation, the incision was closed with staples, which were removed
when the wound was closed but not later than 7 days post-surgery. All procedures were
performed under sterile conditions and according to IACUC approved methods. The
experimental endpoint to evaluate mammary cancer growth in individual genetically
engineered mice or transplant recipients was determined by the maximal size of the
tumor regardless of the health or condition of an animal. The maximal allowed tumor size
was approximately 1.5 cm in diameter as required by the IACUC. Tumor bearing
recipient mice that carried cancer tissues from MMTV-tTA TetO-KrasG12D TetO-H2BGFP or WAP-Cre EF1-LSL-tTA TetO-KrasG12D CAG-GFP females were fed
doxycycline hyclate (Dox, Sigma, #D9891-25G) through the drinking water to suppress
the expression of exogenous mutant KRAS in established mammary tumors. Dox
drinking water contained doxycycline hyclate at a concentration of 2mg/ml and was
supplemented with 0.5mg/ml of D-sucrose to reduce the bitterness of the water (Dox
water by itself is too bitter for the mice and reduces uptake). The duration of Dox
treatment is described in the Results chapter. Tumors were measured at constant intervals
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with an electronic caliper. The longest dimension (length) and the shortest dimension
(width) of the tumors were recorded and tumor volumes were mathematically determined
with the following formula:

Tumor volume =

!"#$%& ()))∗ ,-.%&! ())! )
/

2.8 Histology
Fresh mouse tissue samples (i.e., inguinal mammary glands, mammary tumors, and
lungs) were removed from euthanized mice and spread on a microscope glass slide.
These unfixed samples were examined for GFP expression and imaged with a
Discovery.V8 fluorescence stereoscope (Carl Zeiss, Inc.) equipped with a SPOT Flex
camera. Tissues were subsequently cut into slices of approximately 2mm thickness, if
necessary, to allow for increased fixation buffer penetration. For histological examination
these tissues were placed in at least 50x the tissue volume of 10% buffered formalin
(Fisher Healthcare, #245-684) and fixed for 24 hours at room temperature under
consistent agitation of a shaker. For short-term and long-term storage, the formalin was
poured off after 24 hours and replaced with 70% ethanol (prepared from HistoPrep 100%
Denatured Ethyl Alcohol, Fisher, #HC8001GAL). Tissue was subsequently prepared for
paraffin embedding by placing the tissue into tissue cassettes and were processed with the
Excelsior AS Tissue Processor (Thermo Scientific, #A82300001). This is an automated
process that exposes the tissue to manufacturer recommended solutions, starting with
70% ethanol, followed by water and a gradient of dehydrating solution, clearant solution
and ultimately paraffin. Subsequent paraffin tissue embedding was performed using the
Histostar (Thermo Scientific, # A81000007). Tissues were sectioned to 5µm of thickness
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with a microtome and placed onto coated microscope slides (Fisher Scientific, 12-55015). Tissue section slides were baked overnight at 56°C to remove excess paraffin and
were subsequently suitable for downstream applications.
2.9 Hematoxylin and Eosin (H&E) staining
Sections of paraffin embedded tissue were deparaffinized and hydrated by passing the
slides through the following solutions: (1) three changes of 100% Histo-Clear II
(National Diagnostics, #HS- 202) for 10 minutes each, followed by a sequence of 5minute exposures to (2) twice 100% ethanol, (3) twice 95% ethanol, (4) 70% ethanol, and
finally a short rinse in distilled water. Note that the different ethanol gradients were
produced by diluting HistoPrep 100% Denatured Ethyl Alcohol (Fisher, #HC8001GAL).
After the water rinse, the tissue slides were incubated in Hematoxylin+ (Fisher Health
Care, #220-100) for 5-8 minutes and then rinsed under cold running tap water (ensuring
that the pH of the tap water is within the normal range of water as this can impact the
results) until free of excess hematoxylin. Slides were subsequently differentiated by
dipping them for two seconds into a 1% HCL (in 70% ethanol) solution, followed by a 5minute wash in cold tap water. Bluing was then performed by dipping the slides 20-30
times in 0.2% ammonia water (2ml of ammonium hydroxide in 1000ml of distilled water)
until the sections showed a visible color change to a dark blue/purple. Slides were then
rinsed in cold tap water, dipped into 95% ethanol 20 times, and counterstained with Eosin
Y Stain (Ricca, # 2845-32) for 40 seconds. Afterwards, slides were placed in 95%
ethanol for no more than one minute, followed by dehydration by passing them through
100% ethanol and 100% Histo-Clear II (reverse procedure of what is described above). It
had to be ensured that there was absolutely no water contamination before passing the
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slides into Histo-Clear II as this could lead to formation of water droplets on the slide that
are difficult to eliminate and give the slide a cloudy appearance. Once fully dehydrated
the slides, were mounted using Permount Mounting Medium (Toluene Solution, Fisher
Chemical, #SP15-500) and a glass coverslip. Slides were examined and imaged with a
Zeiss Axio Imager microscope (Carl Zeiss) equipped with a SPOT Flex camera
(Diagnostic Instruments, Inc.), or they were scanned on a brightfield slide scanner from
Leica Microsystems, Inc.
2.10 Immunofluorescence staining
Sections of paraffin embedded tissue were deparaffinized and hydrated by passing the
slides through three changes of 100% Histo-Clear II for 10 minutes each, followed by
decreasing concentrations of ethanol (100%, 100%, 95%, 95%, 70%, 50%, and 30% for 5
minutes each), and finally a 3-minute wash in distilled water. For antigen retrieval, slides
were placed in a rack that was immersed in 1x ImmunoRetriever with Citrate (Bio SB,
#0001QIK02) and pressure cooked for 4 minutes at 116-121°C using a Bio SB
TintoRetriever pressure cooker (Bio SB, #BSB 7008). Slides were allowed to cool to
room temperature and rinsed for 5 minutes in 1x phosphate buffer saline (PBS, Fisher
Bioreagents, #BP399-1). Tissue sections were circled with a hydrophobic pen and, once
dry, the blocking buffer 3% bovine serum albumin (BSA, Sigma, #A9418-100G) in
1xPBS was added on top of the tissue and incubated in a covered wet chamber for 1h.
Subsequently, blocking buffer was removed and replaced with primary antibodies that
were diluted in 3% BSA (in 1xPBS) at concentrations depending on the antibody (Table
2.4). Primary antibody-covered sections were incubated overnight in a sealed wet
chamber at 4°C. The next day, primary antibody was removed, the slides were washed
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three times with 1xPBS for 5 minutes each, fluorophore-conjugated secondary antibodies
(Table 2.5) that were diluted at 1:1000 in 3% BSA (in 1xPBS) were added, and slides
were left to incubate protected from light in a sealed wet chamber for 1 hour. Next, slides
were washed twice for 5 minutes in 1xPBS and once for 5 minutes in distilled water.
Following washing, slides were mounted in the dark with Vectashield DAPI mounting
media (Vector, H-1200), coverslips were applied, and slides were sealed with clear nail
polish. Immunofluorescence stained slides were kept away from light and were examined
and imaged with a Zeiss Axio Imager microscope (Carl Zeiss) equipped with a
fluorescent excitation source and a SPOT Flex camera (Diagnostic Instruments, Inc.).
Table 2.4 List of primary antibodies used for immunofluorescence (IF) staining
Primary Antibodies

Dilutions

Source

Identifier

α-GFP
α-CK8

1:1000

GFP-1020
TROMAI

α-CK14
α-E-cadherin
α-N-cadherin
α-CK5
α-CK6
α-Ki67

1:1000
1:200
1:200
1:200
1:200
1:300

Avēs Labs
Developmental Studies
Hybridoma Bank
Covance
Cell Signaling
Cell Signaling
Covance
Covance
Abcam

1:100

PRB-155P
#3195
#14215
PRB-160P
PRB-169P
ab15580

Table 2.5 List of secondary antibodies used for immunofluorescence (IF) staining
Secondary Antibodies

Source

Identifier

Alexa Fluor 488 goat anti-chicken
Alexa Fluor 488 donkey anti-rat
Alexa Fluor 594 goat anti-rat
Alexa Fluor 594 goat anti-rabbit
Alexa Fluor 594 donkey anti-rabbit
Alexa Fluor 488 donkey anti-rabbit
Alexa Fluor 594 goat anti-mouse
Alexa Fluor 488 donkey anti-mouse

Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen

A11039
A21208
A11007
A11012
A21207
A21206
A11005
A21202
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2.11 Ki-67 quantification
Three representative images (at 400x magnification) were taken of 10 MMTV-Flp FSFKrasG12D p53R172H mammary tumor sections that were immunofluorescence labeled for
the proliferation marker Ki67. The total number of Ki67-positive nuclei and the overall
number of nuclei (indicated by DAPI stain) for each image were counted with the
software Fiji (https://fiji.sc/)132. This allowed determination of the proportion of Ki67positive nuclei to total number of nuclei. The accuracy of the computer-based counting of
nuclei was confirmed by manual counting of select images. GraphPad Prism 6 (GraphPad
Software, La Jolla, CA) was used to perform a paired Student’s t-test to assess
statistically significant differences in cellular proliferation.

2.12 Generation of mammary tumor-derived cell lines
To generate cell lines from mouse mammary tumors, GFP-positive mammary tumors
were removed from the mouse under sterile conditions, washed with sterile 1xPBS, cut
into very small fragments (<1.0mm in diameter), and suspended into 20ml of digestion
medium for each tumor in a 50ml conical centrifuge tube (Fisher Scientific, #14-432-22).
Digestion medium included the following components:
20ml digestion medium:
FBS-free DMEM/F12
100 units/ml Pen/Strep
0.75 units/ml Fungizone
100µg/ml Gentamicin
2mg/ml collagenase (Sigma, #C2674-1G)
100 units/ml hyaluronidase (Sigma, #H3506-5G)

20ml
200µL
60µL
40µL
1.0ml
300µL

Tumor fragments were incubated in digestion medium for a total of 1 hour (or less if
tumor fragments were digested before that timepoint) at 37°C while continuously

44

rotating. Every 15 minutes the cell-break up was aided by a few vigorous shakes. Once
the tumor fragments were mostly digested, the tubes were spun down at 1,000 RPM for 5
minutes and the digestion medium was removed from the cell pellet, which was carefully
resuspended in 10ml of fresh 5%FBS DMEM/F12 medium and transferred into a 15ml
conical centrifuge tube (Fisher Scientific, #14-959-53A). The cells were spun down at
1,000 RPM for 5 min and resuspended an additional four times to ensure that the cell
pellet was completely digestion medium free. For the last resuspension, 6ml of 5%FBS
DMEM/F12 medium were used and 2ml of cell suspension were passed through a cell
strainer (Fisher Scientific, #22-363-547) into each of three wells of a 6-well plate to
achieve a single cell suspension. The cell strainer was flipped over and another 6ml of
media was passed through the filter into three additional wells (2ml each) to gather larger
clusters of cells (organoids). The cells were continuously maintained in 5%FBS
DMEM/F12 media and moved into 10cm cell culture dishes after 2-3 passages. Cells
were monitored for continuous GFP expression and did not show any contamination of
cells that did not express GFP past passage 2-3. The cell lines were all confirmed to be
pure as no GFP-negative cells were observable in these cultures, which was continuously
monitored.

2.13 Cell culture of murine cells
Tumor derived mammary cancer cell lines were maintained in 5% tetracycline-free fetal
bovine serum (FBS, TaKaRa, # 631367) in Dulbecco’s-modified Eagle medium
(DMEM/F12, Gibco, #12400-024) supplemented with 10μg/ml insulin (Gibco, #12585014), 10ng/ml epithelial growth factor (EGF, Gibco, #53003-018), 1mg/ml bovine serum

45

albumin (BSA, Sigma-Aldrich, #A9576-50mL), 5μg/ml linoleic acid-BSA complex (LABSA), 50μg/ml gentamicin (Gibco, #15750-060), 0.25units/ml Fungizone (Amphotericin,
MP Biomedicals, #ICN1672346), 100U/mL Penicillin/Streptomycin (Gibco, #15140122), 1.2g/L sodium bicarbonate (Mallinckrodt Chem., #7412-12), and betamercaptoethanol (Gibco, #21985-023). Cells were split every 4 days when 80-90%
confluent. Fresh mouse embryonic fibroblast (MEF) cells and p53-/- MEFs were grown in
10%FBS MEF medium [DMEM high glucose (Gibco, #11-965-126), FBS, 200 mM LGlutamine (Gibco, #25030-081), 10 mM/100x non-essential amino acids (Gibco,
#11140050), gentamycin, and Penicillin/Streptomycin]. HC11 were grown in 10%FBS
RPMI-1640 medium (Gibco, #11875093), and NIH3T3 cells were grown in 10% bovine
calf serum DMEM.

2.14 Doxycycline treatment of cell lines
For use in cell lines 1mg of Doxycycline hyclate (Sigma, #D9891-25G) was diluted in
1ml of ultrapure water to create a stock concentration of 1mg/ml. This solution has to be
protected from light. To treat cell lines with Dox, cells were split at the normal ratio used
for the maintenance of the cell line. Then, protected from light, 20µL of the stock Dox
was added to the cells (20µL/10ml of culture media). The cell lines were continuously
protected from light and after 48 hours the medium was removed, the cells were washed
with 1xPBS, and fresh medium with 20µL of Dox was added to the cells again. In total
the cells were treated for 72-96 hours.
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2.15 Cell proliferation assay
The proliferation rates of the cell lines was determined by seeding 104 cells into 15 wells
of a 24-well plate (Corning, #3524) for every cell line. After 24h, 48h, 72h, 96h, and
120h, the cells of three wells were collected into separate tubes and the total cell count
for each well was individually determined by counting three replicates for each tube (9
total counts per cell line and time point). Cells were manually counted using trypan blue
solution (Fisher Scientific, #15250061) and a hemocytometer. Consecutive total cell
counts were used to determine the mean proliferation rate. To illustrate changes in
relative proliferation rate between Dox-treated cells and their untreated isogenic controls,
the mean wildtype cell proliferation rate was normalized to 100% and compared to the
mean proliferation rate of Dox-treated cells.

2.16 Development, production, and application of short hairpin RNA (shRNA)
Knockdown construct generation. To knock down the SNAIL protein, two lentiviral gene
transfer vectors were generated by cloning small hairpin sequences (TRCN0000218784
and TRCN0000234034) into the Age1 and EcoR1 sites of the pLKO.1neo vector (gift from
Sheila Stewart to Addgene, #13425).
TRCN0000218784 (5’-CCG GAT GTG TCT CCC AGA ACT ATT TCT CGA GAA ATA
GTT CTG GGA GAC ACA TTT TTT G-3’ and 5’- AAT TCA AAA AAT GTG TCT CCC
AGA ACT ATT TCT CGA GAA ATA GTT CTG GGA GAC ACA T-3’)
TRCN0000234034 (5’-CCG GGA TCT TCA ACT GCA AAT ATT GCT CGA GCA ATA
TTT GCA GTT GAA GAT CTT TTT G-3’ and 5’- AAT TCA AAA AGA TCT TCA ACT
GCA AAT ATT GCT CGA GCA ATA TTT GCA GTT GAA GAT C-3’)
Prior to production of lentiviral particles, the correct sequences of the Snail (Snai1)
shRNAs were validated by Sanger sequencing. To knock down SLUG protein, we obtained
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two previously validated pLKO.1puro shSlug (shSnai2) constructs from Addgene (#40647,
#40648)133.
Lentivirus production. Low passage 293T cells (ATCC®, #CRL-3216™) were cultured in
10%FBS DMEM (antifungal free) until 70% confluent. For transfection two tubes were
prepared. Tube 1 contained 1440µL of FBS-free DMEM and 60µL of Lipofectamine
(Thermo Scientific, #11668030), and tube 2 contained 12µg of helper virus DNA and an
equal amount of plasmid DNA (12µg) + DMEM (no FBS or other additives) for a total of
1500µL. Tubes were vortexed and allowed to incubate for 5minutes at room temperature.
Tube 1 and tube 2 were then combined into a 15ml conical centrifuge tube, vortexed, and
allowed to incubate for 20 minutes. After 20min, the medium from the 293T cells was
removed and cells were carefully washed with 1xPBS to avoid detachment of the cells.
Next, the 3ml from the 15ml tube were carefully added to the 293T cells and incubated at
37°C. After 6 hours, in the evening, 7ml of medium (antibiotic and antifungal free
10%FBS DMEM) was added and incubated at 37°C overnight. The next day at 9:30am,
the 10ml of medium on the 293T cells was aspirated and replaced with fresh 10ml of
antibiotic- and antifungal-free 10%FBS DMEM. At 1:30pm, the medium was aspirated
again and replaced with 3ml of fresh medium. At 5:30pm, the virus was collected by
pipetting the 3ml of medium into a 50ml conical tube (this tube was stored at 4°C for the
remainder of the virus collection. All following virus collections were pooled in this
50mL conical tube. One tube for each shRNA construct). 3ml of fresh medium were
added to the plates and allowed to incubate overnight for continued virus collection the
next day. Virus was collected at the same time intervals the following day by collecting
the 3mL of virus containing media and replacing it with fresh media. The following day

48

one more collection at 9:30am occurred and the 15ml of virus per shRNA construct were
then spun down at 500g to pellet any potential producer cells, and the supernatant was
filtered through a 45µm polyethersulfone (PES) syringe filter (Agilent, #5190-5276) and
aliquoted into 3x5ml into 15ml conical centrifuge tubes. Virus containing tubes were
flash frozen in liquid nitrogen and stored at -80°C until needed.
Infection of cells with lentivirus and selection. Prior to infection of cells with lentivirus,
the cell lines were seeded into the wells of a 6-well plate (3 wells per cell line and
construct). Once the cells had reached approximately 60-80% confluency, the collected
virus was thawed and 10µL of 1mg/ml Polybrene (Sigma-Aldrich, #H9268-5G) per 1ml
of virus was added directly to the virus and inverted to mix. Medium was aspirated off
the cells in the 6-well plates and 600µL of virus was added to each well. The plates were
sealed with parafilm (Fisher Scientific, #S37440) and centrifuged for 80 minutes at 4,000
RPM. Next, 1.5ml of 5% FBS DMEM/F12 (without antibiotics and antifungals) were
carefully added to each well. Medium remained on the cells under normal culture
conditions for another 24 hours and the cells were then transferred into 10cm dishes.
Once confluent, the cells were treated with the appropriate antibiotics for selection. Cells
that were infected with shRNAs that were in the pLKO.1neo backbone were selected
with 400 µg/ml Geneticin® (Gibco, 10131-035), and cells that were infected with
shRNAs that were in the pLKO.1puro backbone were selected with 7 µg/ml puromycin.
Uninfected cells were treated with the same and much lower concentrations of the
antibiotics and died as expected.
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2.17 Flow cytometry
For the flow cytometry experiments, the medium was aspirated off cell lines and the cells
were washed with 10ml of Mg2+/ Ca2+ free 1x phosphate-buffered saline (PBS, Gibco,
#70011-069) at room temperature. Next, 0.05% Trypsin-EDTA (Fisher Scientific,
#25300054) was added to the cells and allowed to briefly incubate until the cells started
to detach from the culture dish. At this point, the trypsin was quenched by adding 2ml of
flow buffer (2% tetracycline-free FBS in Mg2+/ Ca2+ free 1xPBS) and cells were
collected in a 15ml conical centrifuge tube (Fisher Scientific, #14-959-53A) and an
additional 7ml of flow buffer were added to the tube. Cells were centrifuged for 5
minutes at room temperature at 220xg, and supernatant was carefully aspirated to leave
the cell pellets behind, which were resuspended in 10ml of flow buffer. The suspension
was gently pipetted up and down to generate a single cell suspension (NOTE: If larger
chunks or clotting were observed, the suspension was filtered through a 40µm mesh).
Cells were counted using trypan blue solution (Fisher Scientific, #15250061) and a
hemocytometer. At the same time, cells were spun down and resuspend with an
appropriate amount of flow buffer to reach a concentration of 100,000 cells/100µL (1
million cells/ml). 550µL of these cell suspensions were added to a 1.5ml centrifuge tube
and spun down at 220xg for 5min at 4°C. Supernatant was pipetted off and cell pellets
were resuspended in 100µL of flow buffer and an appropriate amount of primary
antibody was added (see Table 2.6). Next, cells were incubated in the dark, while rotating
on an orbital shaker at 4°C for 30min. For the control beads, 1 drop of beads (UltraComp
eBeadsTM Compensation Beads, Thermo Scientific, #01-2222-41) was added to a 1.5ml
centrifuge tube and the same amount of antibody was added as used for the samples.
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Subsequently, 1ml of flow buffer was added to each tube, the tubes were inverted to mix,
centrifuged at 400xg for 4 min at 4 °C, and the supernatant was discarded, leaving the
pellets behind. This washing step was repeated one more time. Finally, the supernatant
was removed and both samples and beads were resuspended in 500µL of flow buffer. The
control beads were added directly to the 5ml round-bottom polystyrene test tubes with
cell strainer snap cap (Fisher Scientific, # 08-771-23), while the samples were forced
through the cell strainer cap to obtain single cell suspensions. The samples were kept on
ice and protected from light until flow cytometric data was acquired on a BD Biosciences
LSRII and analyzed (using FACSdiva 8.0.1 software). Compensation was performed at
the time of acquisition using BD FACSdiva software. The gating strategy was based on
assessing sample quality via SSC-A vs Time and any bubbles or areas of stream
instability were removed prior to analysis. Cells were gated using FSC-A vs SSC-A.
Aggregates were excluded by doublet discrimination using FSC-A vs. FSC-H. Dead cells
were excluded using FSC-A vs. the DAPI viability dye.
Table 2.6 List of antibodies used for flow cytometry
Antibody
CD24-PE
CD49f-PE/Cy7
CD61-APC

Dilution
1:70
1:40
1:100

Source
BD PharmingenTM
BioLegend
Thermo Fisher Scientific

Identifier
#553262
#313621
#MCD6105

2.18 Protein isolation and quantification of cell pellets and mouse tissue
Cell pellets from cell cultures were collected by first washing the cells with cold and
sterile 1xPBS (phosphate buffered saline). Cells were subsequently scraped off the cell
culture dish with a cell scraper (Fisher Scientific, #08-100-241) in 5ml of cold and sterile
1xPBS. Once all cells were suspended in the PBS, the 5ml were transferred into a 15ml
conical centrifuge tubes (Fisher Scientific, #14-959-53A) and spun down at room
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temperature at 1,000 RPM for 5min. Remaining PBS was removed, and the cell pellet
was left behind in the tube. Next, cell pellets were suspended in 30-120µL of complete
lysis buffer containing 1% Nonidet P-40 (Amresco, #E109-100ML), 150mM NaCl
(Fisher Scientific, #PR-V4221), 1 mM phenylmethylsulfonyl fluoride (Amresco, #07545G), 0.4 units/ml aprotinin (Sigma, #A6279), 1 mM NaF (Fisher Scientific, #S299-100),
leupeptin (Midwest Scientific, #J580-2), and 0.1 mM sodium orthovanadate (Sigma,
#S6508). For 500µL of complete lysis buffer mix 471µL NP-40 lysis buffer, 9µL PMSF,
and 5µL each of the remaining proteinase inhibitors were mixed. Once the cell pellets
were suspended in complete lysis buffer, the mixture was sonicated for 3 seconds (with a
Fisher Scientific Model 500 Sonic Dismembrator), left on ice for 30min, spun down at
13,000 RPM for 25 minutes at 4°C, and then the supernatant was transferred into a fresh
1.5ml centrifuge tube. The cell lysate (supernatant) was subsequently quantified by
Bradford protein assay using the Coomassie Plus Assay Kit (Thermo Fisher Scientific,
#23236) and a standard curve was prepared using the bovine serum albumin (BSA)
standard from this kit. Protein concentration was measured using a NanoDrop 2000
(Fisher Scientific, # ND2000). Mouse tissue was suspended in 300-500µL of complete
lysis buffer (see above) and homogenized using an electric tissue homogenizer. The
homogenized tissue was subsequently sonicated for 3 seconds and the remaining protein
extraction and measurement was identical to what was performed for the cell pellets.

2.19 Immunoblot analysis
30-100µg of protein per sample were prepared for analysis by mixing 12.5µL of volumeadjusted protein lysate to 12.5µL of Tris-Glycine SDS Sample Buffer (2x) (Novex,
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#LC2676) and 1µL of beta-mercaptoethanol (Fisher Scientific, #BP176-100). The
samples were heated to 95°C for 10 minutes and loaded immediately onto a WedgeWell
4-20% Tris-Glycine Gel (Invitrogen, #XP04200BOX or #XP04205BOX). Samples were
resolved by applying 80V to the gel that was immersed in 1x Tris-Glycine SDS Running
Buffer (Novex, #LC2675-5) for 3 hours. The gel was subsequently transferred onto a
polyvinylidene fluoride (PVDF) membrane (NOVEX, LC2002) at 150mA for 1.5 hours
followed by another 2.5 hours at 300mA. The transfer buffer used was 1xTris Glycine
Transfer Buffer (NOVEX, #LC3675). Membranes were subsequently blocked for 1 hour
in 5% dry milk in 1xTris-buffered saline with 0.05% Tween-20 (TBST) or 3% bovine
serum albumin (BSA) in 1xTBST for subsequent use of phosphotyrosine-specific
antibodies. After blocking, membranes were incubated overnight at 4°C under agitation
in the corresponding blocking buffer with an appropriate dilution of primary antibody
(see primary antibodies and concentrations in Table 2.7 below). Next day the membranes
were washed three times for 5 minutes with 1xTBST, followed by a one-hour incubation
at room temperature in secondary antibody. Secondary antibody was diluted 1:2,000 in
5% dry milk in 1xTBST (see Table 2.8). Next, membranes were washed five times for 5
minutes with 1xTBST, twice for 5 minutes in 1xTris-buffered saline (TBS), and once for
5 minutes with ultrapure water (Invitrogen, #10977-023). Then, the membranes were
submerged into diluted ECL reagent from the ECL chemiluminescence kit for Western
blot analysis (KwikQuant Ultra Digital-ECLTM Substrate Solution, #R1002). For one
membrane, 0.5ml of each ECL component was diluted with 2-9ml of ultrapure water and
vigorously agitated for 1 minute, which corresponds to the standard instructions by the
manufacturer (Kindle Biosciences, LCC). Protein bands were detected by imaging the
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membrane at consecutive exposure time intervals with a KwikQuant Imager (Kindle
Biosciences, LCC, #D1001). For repeated detection of various proteins on the same
membrane, a mild glycine stripping buffer was used. This buffer is prepared by
dissolving 15g of glycine (Sigma, #G7126-500G), 1g sodium dodecyl sulfate (SDS,
Fisher Bioreagents, #BP2436-1), and 10ml Tween-20 in 800ml of distilled water,
adjusted to a pH of 2.2, and adjusted to 1000ml. The membranes were stripped by
incubating them twice for 10 minutes in mild glycine stripping buffer, followed by two
10-minute washes with 1xPBS, and two 5-minute washes with 1xTBST. The membrane
was then ready for blocking.
Table 2.7 List of primary antibodies used for immunoblotting
Primary Antibodies

Dilution

Source

Identifier

α-KRAS
α-pERK1/2
α-ERK1/2

1:2,000
1:1,000
1:1,000

ab180772
#9101S
#610123

α-GAPDH
α-E-cadherin
α-N-cadherin
α-EpCAM
α-CK14
α-cleaved Caspase 3
α-ITGB3 (CD61)
α-GATA3
α-SLUG
α-SNAIL
α-ERBB2
α-p53
α-MDM2
α-p19Arf/p16Ink4a

1:10,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000
1:1,000

Abcam
Cell Signaling
BD Transduction
Laboratories
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Covance
Cell Signaling
Abcam
Cell Signaling
Cell Signaling
Cell Signaling
Calbiochem
Cell Signaling
Oncogene
Abcam

#5174S
#3195
#14215
#93790S
PRB-155P
#9661S
ab75872
#5852T
#9585T
#3879T
OP-15
#2524T
OP115T-10UG
ab80

Table 2.8 List of secondary antibodies used for immunoblotting
Secondary Antibodies

Source

Identifier

HRP-conjugated goat anti-rabbit
Digital anti-Mouse-HRP

R&D Systems
KwikQuant

HAF008
R1005
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2.20 RNA extraction, library preparation, and RNA sequencing of murine tissue
and cell lines
Total RNA was extracted from MMTV-Flp FSF-KrasG12D p53R172H mammary tumors,
MMTV-tTA TetO-KrasG12D TetO-H2B-GFP mammary tumors, and WAP-Cre EF1-tTA
TetO-KrasG12D CAG-GFP mammary cell lines (untreated and isogenic Dox-treated) using
the RNeasy Mini Kit (QIAGEN, #74106). For each mammary tumor, 25-30g of tissue
was weighed out and immersed into 1000µL of RLT buffer (from RNeasy Mini Kit) in a
14mL round-bottom tube (Fisher Scientific, # 12-565-971) and 10µL of betamercaptoethanol (Fisher Scientific, #BP176-100) were added. The tumors were then
homogenized with an electric homogenizer and kept on ice until the next step. Next,
samples were added to a QIAshredder spin column (QIAGEN, #79656) and spun at room
temperature for 2 minutes at 13,000 RPM (this step aids in lysing the cells and removes
larger cell chunks from the sample). The flow through was additionally spun down in a
new 1.5ml micro-centrifuge tube for 3 minutes at 13,000 RPM. Leaving any cell debris
behind, the supernatant was immediately transferred to a gDNA Eliminator spin column
supplied in the RNeasy Mini Kit. From this point on, the manufacturer’s protocol and
recommendations (QIAGEN, RNeasy® Mini Handbook) were followed to obtain total
RNA from these tumors. For cell lines, cell pellets were processed according to the same
handbook but did not undergo the pre-processing that is required for tumor tissue.
Extracted total RNA was quantified using a NanoDrop 2000 (Fisher Scientific,
#ND2000) and the integrity of the RNA was validated using gel electrophoresis with a
1% E-Gel™ EX Agarose Gel (Invitrogen, #G402001). A minimum of 7µg of highquality total RNA was sent to Novogene who validated the RNA quantity, integrity, and
purity by running the samples on an Agilent 2100 (Agilent, #G2939BA) and performed

55

additional gel electrophoresis. The RNA integrity number (RIN) was assessed as a
measure of RNA integrity, and samples that were of sufficient quality were used for
library construction. All samples passed this quality control and Novogene prepared the
library by first enriching the mRNA using oligo(dT) beads. The mRNA was then
fragmented randomly by adding fragmentation buffer, followed by cDNA synthesis using
the mRNA as template and random hexamer primers. Next, a custom second-strand
synthesis buffer (Illumina), dNTPs, RNase H and DNA polymerase I were added to
initiate the second-strand synthesis. Subsequently, a series of terminal repair, A-ligation,
and sequencing adaptor ligation was performed. Finally, the double-stranded cDNA
library was completed by selecting the fragments for size and subsequent PCR
enrichment. The library quality was confirmed by analyzing it with a Qubit 2.0
(Invitrogen, #Q32866) to test the library concentration, followed by running it on an
Agilent 2100 to test the insert size, and finally Q-PCR to quantify the precise library
concentration. The libraries were then 150bp paired-end sequenced on an Illumina
NovaSeq 6000 to produce more than 20 million read pairs per sample, which we obtained
in the form of FASTQ (raw sequencing reads) files.

2.21 RNAseq differential gene expression- and gene set expression analysis (GSEA)
Differential gene expression analysis. To identify which genes are differentially
expressed between Dox-treated cell lines and untreated cell lines, R language-based134
differential gene expression analysis was performed on the raw RNAseq data that we
obtained from Novogene. Quality control was performed with the R package fastqcr135 on
FASTQ files (containing the raw reads) and confirmed the high quality of the data (Phred

56

score >35). Next, the raw sequencing reads had to be aligned to the mouse mm10
reference genome. For this purpose, the Rsubread package136 was used to first build an
index for the reference genome using the buildindex function and the genome.fa file of
the mm10 reference genome available from UCSC (http://genome.ucsc.edu/cgibin/hgGateway?db=mm10), followed by alignment of the raw 150bp paired-end reads to
the mm10 reference genome with the align function. Next, the resulting BAM files were
used to determine the transcript abundance using the featureCounts function from the
Rsubread package. This alignment pipeline is recommended by the developers of the
edgeR package137,138, which was used for subsequent differential expression analysis.
Transcripts with low abundance (cpm <=5) in more than half of the samples were
excluded from the subsequent analysis. However, to ensure that no bias was introduced
by this filtering method, the exclusion of transcripts was independent of which samples
showed low transcript abundance. Since the sequencing data was derived from isogenic
cell line pairs (i.e., Dox-treated and untreated) a paired sample differential expression
analysis approach was chosen to detect genes that are differentially expressed between
the Dox-treated and untreated samples, adjusting for any differences between different
cell lines. The edgeR package was used to normalize the data, estimate the dispersion,
and to determine the differentially expressed genes using the functions glmFit and
glmLRT. Genes that showed differences in expression between the untreated and Doxtreated samples by more than 2-fold and an FDR (False Discovery Rate) of below 0.001
were considered as significantly deregulated.
Gene Set Enrichment Analysis (GSEA). Based on the output of the differential gene
expression analysis, a GSEA was performed with the gseKEGG function and plotted with
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gseaplot from the clusterProfiler package (v3.0.4)139 to determine differences between
Dox-treated and untreated cells in Kyoto Encyclopedia of Genes and Genomes (KEGG)
annotated pathways. To visualize the genes that were significantly deregulated within
select enriched pathways, the transcript count data was log2 transformed, significantly
deregulated genes were extracted, and finally plotted with the R-function heatmap.2 from
the gplots package (v3.0.3)140.

2.22 Generation of bigWig files and gene expression visualization
To visualize the gene expression data from our RNAseq experiments, we converted BAM
files into bigWig files, which can be viewed with The Broad Institute’s Integrative
Genomics Viewer (IGV). First, the FASTQ files were aligned to the mm10 mouse
reference genome using Rsubread, which resulted in the generation of BAM files. These
BAM files were subsequently sorted and indexed using the samtools package141 through
the MAC Terminal program. The last step was to generate cpm-normalized bigWig files
from these sorted and indexed BAM files using the bamCoverage function from the
deepTools2 package142.

2.23 Hierarchical cluster analysis of microarray and RNAseq gene expression data
Microarray hierarchical cluster analysis. Total RNA that was isolated from MMTV-tTA
TetO-KrasG12D TetO-H2B-GFP and WAP-Cre EF1-tTA TetO-KrasG12D CAG-GFP
mammary tumors was processed and labeled for microarray analysis as previously
described by Pfefferle et al.93 and subsequently hybridized to Agilent Mouse 430A 2.0
arrays. Gene expression was recorded, and sample-standardized and gene median-centered
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data from new samples were combined with 385 previously described microarray analyses
from mouse mammary tumors from various genetically engineered mouse models (GEMMs).
For a full list of all reference samples, please refer to Pfefferle et al.93 or see section “Data

and software availability” for a list of Gene Expression Omnibus (GEO) accession
numbers. Normalized samples were hierarchically clustered and classified using the
centroid method in Cluster3.0143 and the set of ~1800 intrinsic murine genes described by
Pfefferle et al.93. The cluster tree and corresponding heatmap was visualized using Java
TreeView144.
RNAseq hierarchical cluster analysis. Paired-end (2x150bp) sequencing was performed
on total RNA isolated from mammary tumors of MMTV-Flp FSF-KrasG12D p53R172H on
an Illumina NovaSeq 6000 by Novogene. The resulting FASTQ files were aligned to the
mm10 mouse reference genome using the STAR alignment method145. The resulting
BAM files were sorted and indexed using samtools141, followed by quality control with
Picard (http://broadinstitute.github.io/picard). Next, transcript read counts were
determined using Salmon146, genes that showed zero reads across all samples were
removed. Our new samples were integrated with the reference models (see Table 2.9) and
gene-level counts were upper quartile normalized147. Genes that showed zero counts in
more than 30% of samples were removed and log2 transformed using Cluster3.0. Zero
counts were preserved. The expression data was then median centered and column
standardized to establish the appropriate matrix for subsequent analyses. Hierarchical
clustering was performed with Cluster3.0 using the intrinsic murine gene set and was
then visualized with Java TreeView. Reference data sets come from previously published
RNAseq data from a variety of murine mammary tumor and normal samples (see Data
Availability section, or Table 2.9).
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Table 2.9 List of mouse references for RNAseq-based hierarchical cluster analysis
External code
Wnt1-172499
Wnt1-468512
Wnt1-168508
Wnt1-167209
Wnt1-169918
Wnt1-171984
Wnt1-171979
FVB_MMTV_Wnt1_182352_Early
FVB_MMTV_Wnt1_183983_Early
FVB_MMTV_Wnt1_183984_Early
FVB_MMTV_Wnt1_123070_Early
FVB_MMTV_Wnt1_123738_Early
FVB_MMTV_Wnt1_124328_Early
FVB_MMTV_Wnt1_182281_Early
FVB_MMTV_Wnt1_126355_Early
FVB_MMTV_Wnt1_172215_Late
FVB_MMTV_Wnt1_174861_Late
FVB_MMTV_Wnt1_175317_Late
FVB_MMTV_Wnt1_124326_Late
FVB_MMTV_Wnt1_125673_Late
FVB_MMTV_Wnt1_125285_Late
FVB_MMTV_Wnt1_123114_Late
FVB_MMTV_Wnt1_123420_Late
Wnt1 169927.1
Wnt1 169927.2
Wnt1 171053
K14 150484_Prim
K14 149722_ Prim
K14_157391_Prim
K14_154180_Prim
K14_154160_Prim
K14_154140_Prim
K14_152904_Prim
K14_152445_Prim
K14_157209_Prim
K14_151884_Prim
K14_152422_Prim
K14_151363_Prim
K14_153084_Prim
K14_151591_Prim
K14_153560_Prim
K14_152479_Prim
K14_155877_Prim
K14_152940_Prim
K14_151241_Prim
K14_153561_Prim
K14_ A_ 166044 _P4
K14_ B_ 160997 _P4
K14_ A_ 159063 _P2
K14_ B_ 159063 _P2
JU-309N-Bc-mmg
K14-KPB1-A-153560 org
K14-KPB1-A-CC264
K14-KPB1-B-154160 org
K14-KPB1-B-CC215
2225L-DH481
2224-MP1U-7

Model
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB MMTV-wnt1
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
Balb/c wt
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/-

GEO Series
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE118164
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821

GEO Sample
GSM3319725
GSM3319726
GSM3319722
GSM3319723
GSM3319721
GSM3319720
GSM3319724
GSM3319732
GSM3319735
GSM3319741
GSM3319731
GSM3319729
GSM3319737
GSM3319738
GSM3319739
GSM3319742
GSM3319733
GSM3319728
GSM3319734
GSM3319730
GSM3319740
GSM3319736
GSM3319727
GSM3319718
GSM3319717
GSM3319719
GSM3554752
GSM3554753
GSM3554767
GSM3554766
GSM3554763
GSM3554758
GSM3554754
GSM3554762
GSM3554765
GSM3554764
GSM3554761
GSM3554755
GSM3554757
GSM3554759
GSM3554756
GSM3554760
GSM3554770
GSM3554769
GSM3554751
GSM3554768
GSM3554682
GSM3554687
GSM3554683
GSM3554688
GSM3554775
GSM3554773
GSM3554774
GSM3554772
GSM3554771
GSM3554808
GSM3554789
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FVB Mammary 1
FVB Mammary 2
BalbC Mammary 1
BalbC Mammary 2
2336R-PBS-p53null-MP1U38
PYMT-2139-4-E2FWT-ST
PYMT-2680-1-E2FWT-ST
PYMT-628-3-E2FWT-ST
PYMT-3136-5-E2FWT-ST
PYMT-455-3-E2FWT-ST
B4532-4R-ILC-ST
B4538-3L-ILC-ST
B4540-5L-ILC-ST
B4589-3L-ILC-ST
B4535-1R-ILC-ST
B4657-5L-ILC-ST
B4713-5L-ILC-ST
B4513-5R-ILC-ST
B4894-5L-ILC-ST
B4894-5R-ILC-ST
BalbC3-pooledMAMM
BalbC4-pooledMAMM
FVB4-pooledMAMM
FVB5-pooledMAMM
BalbCp53null-Tumor9263-3-F
DH633_kpb25L_3day_NT
DH627_kpb25L_NT
DH606_kpb25L_NT
DH605_NT_KPB_25L
DH632_kpb25L_3DAY_nt
DH625_kpb_25L_nt
MP1U37_2336R_pbs
MP1U5_2336R_pbs
MP1U38_2336R_pbs
MP1U1_2336R_pbs
DH482_2225L_3day_NT
DH447_2225L_3day_NT
DH494_2225L_NotTreated
DH443_2225L_NotTreated
DH448_2225L_NotTreated
DH861_2336R_3day_nottreated
DH851_2336R_NotTreated
DH852_2336R_3day_notTreated
DH742_KPB25L_3day_NotTreated
DH850_2336R_3dayNotTreated
DH871_2225L_3day_nt
DH862_2225L_3day_nt
KPB_25L_V1_5_CELL_LINE
T11_V5_CELL_LINE
KPB_EF1A_APOBEC_CELL_LINE
BalbCp53null-2224L
BalbCp53null-2225L
BalbCp53null-2336R
FVB-nJ-KPB1-A
KM277-2153F-5mm
KM278-2153F-5mm
KM279-2153F-5mm
KM-280-2153-5mm
DH932-T11-Reg-nt-3day

FVB wt
FVB wt
Balb/c wt
Balb/c wt
Balb/c p53-/FVB PyMT
FVB PyMT
FVB PyMT
FVB PyMT
FVB PyMT
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
ILC-Pik3Ca/Cdh1Null
Balb/c wt
Balb/c wt
FVB wt
FVB wt
Balb/c p53-/FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
Balb/c p53-/FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/-

GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821

GSM3554780
GSM3554781
GSM3554776
GSM3554777
GSM3554828
GSM3554868
GSM3554869
GSM3554870
GSM3554871
GSM3554872
GSM3554873
GSM3554874
GSM3554875
GSM3554876
GSM3554877
GSM3554878
GSM3554879
GSM3554880
GSM3554881
GSM3554882
GSM3554778
GSM3554779
GSM3554782
GSM3554783
GSM3554834
GSM3554704
GSM3554713
GSM3554714
GSM3554711
GSM3554703
GSM3554712
GSM3554825
GSM3554823
GSM3554824
GSM3554822
GSM3554796
GSM3554795
GSM3554806
GSM3554804
GSM3554805
GSM3554814
GSM3554826
GSM3554813
GSM3554705
GSM3554815
GSM3554798
GSM3554797
GSM3554678
GSM3554845
GSM3554679
GSM3554790
GSM3554807
GSM3554827
GSM3554684
GSM3554785
GSM3554786
GSM3554787
GSM3554788
GSM3554924
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DH933-T11-Reg-nt-3day
DH934-T11-Reg-nt-3day
DH935-T11-Reg-nt-3day
KM272-2224L-5mm
KM273-2224L-5mm
KM275-2224L-5mm
KM274-2224L-5mm
KM372-KPB1-A-5mm-NT
KM375-KPB1-A-5mm-NT
TumorT12-VAL
KM414-9263-3-5mm-nt
KM427-9263-3-5mm-nt
KM421-9263-3-5mm-nt
KM420-9263-3-5mm-nt
DH925-T11-NT-End
DH904-KPB25L-NT-END-Flow
DH907-KPB25L-NT-End-Flow
DH905-KPB25L-5mm-Nt-flow
DH908-KPB25L-5mm-Nt-flow
DH927-T11-NT-END
DH931-T11-NT-END
DH953-T11-NT-END
DH959-T11-NT-END
T-11-CellLine-VALIDATION
KPB-25L-CellLine-VALIDATION
DH1472-T11-7Day-NT
DH1473-T11-7Day-NT
DH1474-T11-7Day-NT
DH1475-T11-7Day-NT
DH1044-KPB25L-NT-7day
DH1044-KPB25L-NT-7day-repeat
DH1046-KPB25L-NT-7day
DH1039-KPB25L-NT-7day
C3TAG 135478
C3TAG 136827
C3TAG 148641
C3TAG 150376
C3TAG 166232
C3TAG 165961
C3TAG 165962
KPB1-A 173328
KPB1-A 173329
KPB1-B 173334
KPB1-B 173335
T12
2245R
T7
2336R
T1
T2
T6
2151R
C3TAG-158413
C3TAG-159447
C3TAG-159450
C3TAG-160056
Neu-NT7d-LH73
Neu-NT7d-LH84
Neu-NT7d-164606

Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
C3 TAg
C3 TAg
C3 TAg
C3 TAg
C3 TAg
C3 TAg
C3 TAg
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
FVB K14-p53-BRCA1 mut
Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/Balb/c p53-/C3 TAg
C3 TAg
C3 TAg
C3 TAg
FVB MMTV-neu
FVB MMTV-neu
FVB MMTV-neu

GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE124821
GSE148482
GSE148482
GSE148482

GSM3554925
GSM3554926
GSM3554927
GSM3554791
GSM3554792
GSM3554794
GSM3554793
GSM3554680
GSM3554681
GSM3554867
GSM3554835
GSM3554838
GSM3554837
GSM3554836
GSM3554921
GSM3554699
GSM3554701
GSM3554700
GSM3554702
GSM3554922
GSM3554923
GSM3554934
GSM3554935
GSM3554846
GSM3554723
GSM3554896
GSM3554897
GSM3554898
GSM3554899
GSM3554693
GSM3554694
GSM3554695
GSM3554692
GSM3554675
GSM3554670
GSM3554674
GSM3554673
GSM3554676
GSM3554671
GSM3554672
GSM3554685
GSM3554686
GSM3554689
GSM3554690
GSM3554840
GSM3554812
GSM3554843
GSM3554821
GSM3554839
GSM3554841
GSM3554842
GSM3554784
GSM3554667
GSM3554677
GSM3554668
GSM3554669
GSM4471878
GSM4471879
GSM4471877
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2.24 Data and software availability
All RNAseq data generated in this dissertation was deposited in the Gene Expression
Omnibus (GEO) under the accession number GSE157333. Other data that was used for
the cluster analysis is available under the GEO accession numbers GSE118164,
GSE124821, GSE148482, GSE3165, GSE8516, GSE9343, GSE14457, GSE15263,
GSE17916, and GSE27101, and GSE42640.

2.25 Statistical analysis
All graphic illustrations and statistics were produced with GraphPad Prism 6 software
(GraphPad Software, Inc., La Jolla, CA), except for the RNAseq and microarray-based
graphics and statistics. Visualization of data and statistical analyses from these genomic
experiments are described in their corresponding sections. All reported measurements
were taken from distinct samples and, unless otherwise indicated in the figure legends,
experimental data are presented as mean values ± standard error (SE) or mean ± standard
deviation (SD). Prior to performing statistical analyses, data was assessed for normality.
Statistical tests performed in this work include Student’s t test, Mann-Whitney-Wilcoxon
test, or one-way ANOVA and Tukey's multiple comparison test. The logrank test was
used to assess tumor-free survival distributions between animals. P-values < 0.05 (∗), <
0.01 (∗∗) or < 0.001 (∗∗∗) were considered statistically significant. Differentially
expressed genes were considered significantly deregulated if they differed by 2-fold or
more and showed an FDR below 0.001. For a detailed description of underlying
statistical methods used for differential gene expression analysis, please refer to Chen et
al.148.
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Chapter 3: Results
Part of the results presented in this chapter were previously published:
Sakamoto, K.*; P.D. Rädler*; B.L. Wehde; A.A. Triplett; H. Shrestha; R.-M. Ferraiuolo;
F. Amari; V. Coppola; A. Klinakis; Argiris Efstratiadis and K.-U. Wagner (2020):
Efficient tissue-type specific expression of target genes in a tetracycline-controlled
manner from the ubiquitously active Eef1a1 locus.
Sci. Rep. 10 (1): 207
* contributed equally

64

3.1 Oncogenic RAS signaling leads to the development of poorly differentiated,
triple-negative mammary carcinomas of diverse subtypes that are capable of
metastasizing
To assess whether oncogenic Ras signaling can cause triple-negative mammary tumors,
we set out to establish a mouse model that expresses KrasG12D under the control of the
tetracycline-responsive transactivator in the mammary epithelium of female mice (Fig.
3.1A). Our laboratory previously generated the MMTV-tTA transgenic mouse model for
the targeted, conditional expression of genes in the embryonic and postnatal mammary
gland149. In this model, the tetracycline transactivator (tTA) transgene is coupled to the
mouse mammary tumor virus (MMTV) promoter, which leads to the stable expression of
the Dox-repressible tTA (Tet-OFF) protein specifically in the mammary epithelium (and
in the salivary glands) as early as day 14.5 of embryonic development and onward. To
express the desired KrasG12D mutant in this mammary gland specific manner, it must be
coupled to the TetO transgene, containing the Tet-operon linked to a minimal promoter
from the human cytomegalovirus immediate early gene 1. In the presence of tTA, the
TetO-coupled responder gene (KrasG12D) is constitutively expressed through binding of
the tTA to the Tet-operon. We obtained TetO-KrasG12D [Tg(tetO-Kras2)12Hev/J]125
transgenic mice from the Jackson Laboratory and bred them with our MMTV-tTA
transgenic mice. For temporal and spatial visualization of the MMTV-tTA mediated
transgene expression, we additionally crossed the TetO-H2B-GFP (Tg(tetOHIST1H2BJ/GFP)47Efu/J)126 reporter transgene into our bi-transgenic mice, resulting in
triple-transgenic MMTV-tTA TetO-KrasG12D TetO-H2B-GFP experimental mice.
Successful expression of the tetracycline transactivator in this triple-transgenic mouse
model is indicated by the presence of nuclear green fluorescent protein (GFP), which is
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an indicator that the tTA is simultaneously also activating the expression of oncogenic
Kras (KrasG12D).
To confirm the expression of KrasG12D and the associated expression of the
nuclear green fluorescent protein (GFP), adult females were sacrificed, and their
mammary glands were removed and imaged with a fluorescent stereoscope. Widespread
GFP-positivity throughout the epithelial mammary ductal tree, as well as in secretory
alveoli of lactating females, confirmed the MMTV-tTA-mediated activation of the TetOH2B-GFP and TetO-KrasG12D responder transgenes (Fig. 3.2A). To obtain a more
detailed picture of the expression pattern, we stained mammary gland tissue with celllineage specific markers. The adult mammary gland epithelium is comprised of two main
cell types, basal and luminal cells, which are easily distinguishable by the staining of
corresponding cytokeratins. Cytokeratins are cytoskeletal keratins that occur in epithelial
cells, and several of them have been established as lineage markers within the mammary
epithelium. Expression of cytokeratin 5 and 14 (CK5 and CK14) marks
myoepithelial/basal cells, and cytokeratin 8 and 18 (CK8 and CK18) expression marks
the luminal cell lineage76. To determine the subset of cells in the mammary gland
epithelium that predominantly expressing the MMTV-driven tTA, the mammary glands
were fixed, paraffin embedded, and sectioned to 5µm tissue thickness. Coimmunofluorescence staining of GFP and CK8, or GFP and CK14, revealed that a large
majority of cells that express nuclear GFP reside within the CK8 positive, luminal
epithelial compartment (Fig. 3.2B, left). In rare instances, nuclear GFP positivity was
also detected in cells that were positive for the myoepithelial/basal marker CK14 (Fig.
3.2B, right). However, less than 1% of all stained cells showed co-expression of CK14
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and GFP. These results indicate that the MMTV-tTA transgene is preferentially active in
the luminal epithelial compartment in mammary glands of adult females.
Next, we observed that the MMTV-tTA-mediated, constitutive activation of
mutant Kras in the mammary epithelium was sufficient to initiate palpable mammary
tumor growth after a mean latency of 160 ±41 days after birth (Fig. 3.1A, right). To
exclude the possibility of single-transgenic TetO-KrasG12D mice developing mammary
tumors, the mammary glands of age-matched control females were analyzed. Single
transgenic TetO-KrasG12D control mice did not develop any neoplastic lesions and
showed no other abnormalities compared to a wild type mammary gland. Therefore,
mammary tumor development is not caused by the transgene integration site into the
DNA but is caused by the expression of KrasG12D in the mammary gland epithelium.
Expression of GFP throughout the mammary tumors of triple transgenic MMTV-tTA
TetO-KrasG12D TetO-H2B-GFP females confirmed that the expression of KrasG12D was
sustained throughout the neoplastic transformation and tumor progression. Hematoxylin
and Eosin (H&E) staining of the mammary tumors of female MMTV-tTA TetO-KrasG12D
mice and subsequent histopathological examination revealed diverse morphological
features. Most tumors were classified as poorly differentiated large-cell carcinomas with
areas of local invasion and epithelial-mesenchymal transition (EMT) (Fig. 3.1B, top).
Next, I characterized the tumors by immunofluorescence staining of CK8 and CK14 (Fig.
3.1B, bottom). All tumors showed a heterogeneous mixture of CK8 positive and CK14
positive cells. Interestingly, many cells stained positive for both CK8 and CK14 (dual
positive), including in areas where the cells showed an elongated, spindle-cell
morphology. In contrast to the more cuboidal-shaped epithelial cells, however, the
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spindle-shaped cells showed a weaker staining intensity of both cytokeratins. Particularly
CK8 staining was reduced in these spindle-shaped cells that are commonly associated
with invasive EMT characteristics. Since we observed predominant MMTV-mediated
tTA expression in luminal epithelial cells in untransformed mammary glands and the
subsequently arising mammary tumors show a much higher proportion of CK14 or dual
positive cells, we considered the possibility that oncogenic KRAS signaling might cause
luminal cells to acquire basal-like features.
To further characterize the biological properties of these mammary tumors, we
transplanted GFP+ tumor fragments into the number 4 mammary glands (#4 MGs) of
wild type recipient mice. Transplanted tumors recurred within 21 days of transplantation
and maintained the histological features of the primary tumors (Fig. 3.1C, left).
Interestingly, we observed a partial enrichment of EMT features in one case where the
primary tumor already showed more extensive areas of EMT than typically observed. To
evaluate the mammary tumors’ invasive and metastatic capabilities, we inspected the
mice for metastatic lesions and observed that 28 out of 42 (66.6%) recipient females
displayed pulmonary metastases at the time of necropsy (Fig. 3.1D, left). Metastatic
lesions were easily identifiable with a fluorescent stereoscope due to the maintained
expression of the nuclear GFP reporter, which indicates the continued expression of
oncogenic Kras throughout the metastatic process and cancer cell proliferation at distant
sites. Histopathological analysis of H&E-stained pulmonary tissue confirmed the
presence of macroscopic and microscopic metastatic lesions that consistently showed
nuclear expression of GFP when stained via immunofluorescence staining (Fig. 3.1D,
middle and right). So far, we established that expression of oncogenic Kras (KrasG12D) in
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the mammary epithelium, predominantly in the luminal compartment, is sufficient to give
rise to mammary tumors that frequently metastasize to distant sites while continuously
maintaining KrasG12D expression. To test whether these tumors are dependent on
continuous oncogenic Kras signaling in vivo, tumor-bearing mice were treated with
doxycycline (Dox) through the drinking water. Our triple transgenic mouse line is based
on the Tet-OFF systems, which allows for the disruption of tetracycline transactivator
(tTA) binding to the TetO in the presence of tetracycline or its derivatives such as
doxycycline. Dox treatment through the drinking water, therefore, prevents tTA from
activating the transcription of KrasG12D and H2B-GFP, which lead to a complete
macroscopic regression of the mammary tumors within ten days (Fig. 3.1E). This finding
suggests that the vast majority of tumor cells are dependent on continuous oncogenic
Kras signaling for their survival. However, analysis of immunofluorescence-stained
tissue sections of Dox-treated mice revealed that residual cancer cells remained in the
mammary gland at a microscopic level, even when the mice had been on Dox for more
than 21 days (Fig. 3.1F). Nuclear H2B-GFP positivity of the residual cancer cells in the
primary and metastatic site suggests that these cells are quiescent (dormant) or progress
very slowly through the cell cycle. Since H2B-GFP is integrated into histones, cells that
are treated with Dox and continue to go through the cell cycle quickly lose detectable
GFP expression as Dox represses new transcription of H2B-GFP. Thus, GFP is diluted
out with every cell division. In the prolonged presence of Dox, detectable GFP
expression is, therefore, a consequence of arrested cell cycling or very slow progression.
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Figure 3.1 Expression of oncogenic KRAS under the control of the MMTV-tTA is
sufficient to initiate the development of poorly differentiated mammary carcinomas
A. Schematic outline of the transgenes (left) and the Kaplan-Meier survival curve (right)
of mice that expresses oncogenic KRAS and the H2B-GFP reporter in a doxycycline
(Dox)-controlled manner in the mammary epithelium. B. H&E and immunofluorescence
staining of CK8 and CK14 on tissue sections derived from mammary tumors expressing
oncogenic KRAS; scale bars represent 200 µm (upper) and 50 µm (lower). C.
Histological sections of transplanted tumors; scale bar represents 100 µm. D. Pulmonary
metastasis rate in tumor-bearing mice and histological section of a pulmonary metastasis
with a serial section of immunofluorescence-labeled H2B-GFP; scale bar represents 100
µm. E. Tumor growth curves in wildtype recipient mice that were engrafted with mutant
KRAS expressing mammary tumor cells (-Dox). Mice with secondary tumors of about
500 mm3 in volume were treated for up to 24 days with doxycycline (+Dox) to suppress
oncogenic KRAS. F. Residual cancer cells in lung tissues of Dox-treated recipients
immunofluorescence-labeled for H2B-GFP and CK14; bars represent 50 µm.

70

Figure 3.1

71

Figure 3.2 The MMTV-tTA-mediated activation of the TetO-H2B-GFP reporter is
predominantly restricted to luminal epithelial cells
A. GFP fluorescent stereoscopic images of fresh mammary gland tissues from
nonpregnant and lactating MMTV-tTA TetO-H2B-GFP double transgenic females; bars
represent 1 mm. B. Immunofluorescence co-staining of GFP and luminal Cytokeratin 8
(CK8) or basal-lineage marker Cytokeratin 14 (CK14) on serial mammary gland sections
from a nonpregnant MMTV-tTA TetO-H2B-GFP female; bars represent 50 μm.
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3.2 MMTV-tTA-based expression of mutant KRAS predominantly leads to the
formation of poorly differentiated luminal-like mammary tumors
To determine if mutant Kras expression leads to the formation of mammary tumors that
fall within one or more of the previously defined mammary cancer subgroups, we
performed a microarray-based gene expression analysis on four RNA samples, followed
by unsupervised hierarchical clustering. The samples were derived from four different,
poorly differentiated mammary carcinomas that originated in MMTV-tTA TetO-KrasG12D
TetO-H2B-GFP females. One of the tumors included in this analysis showed extensive
EMT-characteristics in the form of spindle-shaped cells. Unsupervised hierarchical
clustering based on select microarray gene expression values revealed that three of the
four mutant Kras-driven tumors clustered to reference mammary tumors that originated
from MMTV-HRAS, WAP-Int3, and WAP-Myc transgenic females (Fig. 3.3, yellow
arrows on the left). Tumors of this cluster fall into the Class8 tumor types, which belong
to a larger group of mouse models that develop luminal-type mammary tumors such as
MMTV-neu and MMTV-PyMT. Interestingly, among this larger subgroup of luminal
mammary tumor types, Class8 mammary tumors are typically among the least
differentiated150. The mammary tumor that had shown increased mesenchymal/ EMTfeatures in the histopathological analysis clustered to the claudin-low subtype (Fig. 3.3,
yellow arrow on the right). Evaluation of Cldn3, Cldn4, and Cldn7 expression confirmed
that this tumor does not express these claudins, which is consistent with the claudin-low
subtype. Lack of Cdh1 (E-cadherin) gene expression and increased Cdh2 (N-cadherin)
gene expression was also observed, while the other three mammary tumors maintained
Cdh1 expression and did not show increased levels of Cdh2. We performed an additional
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RNAseq experiment on these mammary tumors to validate these gene expression
findings and visualized the exome-based gene expression with the Integrative Genomics
Viewer (IGV) from the Broad Institute (Fig. 3.4). Visualization of gene expression did
not only confirm the microarray-based gene expression results but also confirmed that all
of these tumors lack the gene expression of estrogen receptor a (Esr1) and progesterone
receptor (Pgr).
Based on this histopathological and molecular characterization, it is apparent that
MMTV-tTA-mediated oncogenic KRAS signaling in the mammary epithelium is
sufficient to initiate the development of poorly differentiated, triple-negative mammary
carcinomas that can metastasize to distant organs. Determination of the molecular
subtypes of these mammary tumors revealed that most of them share characteristics with
poorly differentiated luminal-type tumors, despite showing expression of luminal and
basal cytokeratins on the histological level. We also showed that the progression of
MMTV-tTA TetO-KrasG12D mammary tumors into the claudin-low molecular subtype is
a rare event. Independent of the histological and molecular characteristics, continuous
oncogenic KRAS signaling was essential for the proliferation and survival of the large
majority of primary and metastatic cancer cells. This dependence on continuous KrasG12D
expression combined with the partial transition of luminal cells into basal-like cells
within the mammary tumors intrigued us as we had anticipated the development of basallike or claudin-low mammary tumors.
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Figure 3.3 The mode of oncogenic KRAS expression determines the molecular
subtype of mammary cancers
Microarray-based gene expression and unsupervised hierarchical cluster analysis to
classify and compare the molecular profiles of mammary tumors that originated in
MMTV-tTA TetO-KrasG12D (yellow arrows) and WAP-Cre EF1-tTA TetO-KrasG12D (red
arrows) transgenic females with reference sets from diverse genetically engineered as
well as chemical- and radiation-induced mammary cancer models. In both models, the
TetO-KrasG12D transgene is under control of the tetracycline-responsive transactivator
(tTA). In contrast to the mammary epithelial-specific expression of the tTA under the
control of the MMTV-LTR, the WAP-Cre-mediated activation of oncogenic KRAS in the
luminal epithelium is under control of the ubiquitously active EF1-tTA, which is
untethered from a differentiation state and allows neoplastic cells to assume diverse
developmental fates.
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Figure 3.4 Class8 and claudin-low MMTV-tTA-mediated mammary tumors display
distinct expression of genes associated with the claudin-low subtype
RNA-sequencing histograms of bonafide claudin-low markers including claudin 3
(Cldn3), claudin 4 (Cldn4), claudin 7 (Cldn7), E-cadherin (Cdh1), N-cadherin and (Cdh2)
in mammary tumors derived from MMTV-tTA TetO-KrasG12D females. Additional gene
expression histograms for estrogen receptor alpha (Esr1) and progesterone receptor
(Pgr).
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3.3 Eef1a1-mediated expression of the tetracycline transactivator (tTA) allows for
cell type specific initiation and continuous, differentiation-independent activation of
responder transgenes
To establish the MMTV-tTA mouse model, the tetracycline transactivator (tTA) was
placed under the control of the mouse mammary tumor virus long terminal repeat
(MMTV-LTR) regulatory element. Through genetic labeling, we have shown that the
activation of MMTV-tTA is limited to the mammary epithelium of murine mammary
glands and occurs predominantly in luminal cells. Preferential activation of the MMTVLTR regulatory element in luminal epithelial cells of adult mammary glands may be
explained by the natural life cycle of the mouse mammary tumor virus (MMTV). The
MMTV is naturally transmitted through milk from the mother to the offspring via viral
shedding by infected, milk-producing cells151. These milk-producing, luminal mammary
epithelial cells are, therefore, an essential cell type for the life cycle of the virus.
Additionally, it is known that, while MMTV-LTR is active in the mammary epithelium
of nulliparous females, the expression is elevated in pregnant and lactating females due to
steroid hormone and prolactin response elements that are part of the long terminal repeat
(LTR)152. The 2.4kb MMTV-LRT construct has also previously shown to be highly
responsive to glucocorticoid stimulation and in vitro shows a 100-fold increase in
MMTV-LTR mediated expression upon stimulation153. Because these hormones play an
essential role in the functional differentiation and proliferation of luminal epithelial cells,
it is not surprising that the MMTV-LTR is predominately active in this particular
mammary epithelial cell lineage. Since most cancer cells of our MMTV-tTA TetOKrasG12D model are dependent on continuous oncogene expression for their survival, the
MMTV-LTR likely restricts transdifferentiation of luminal-type cancer cells into a
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complete basal-type or mesenchymal-like state. Significantly reduced MMTV-mediated
expression of tTA and the dependent oncogenic driver (KrasG12D) in cancer cells that
undergo a transition into a mesenchymal state would lead to their negative-selection (Fig.
3.5). Based on these observations, it is likely that mammary tumors that arise from
MMTV-tTA TetO-KrasG12D females are constrained to a predominantly luminal-like state
due to the intrinsic biological features of the MMTV-LTR and the dependence of these
tumors on the continuous expression of the oncogenic driver KrasG12D. To assess the full
developmental potential of mammary cancer cells and their ability to transdifferentiate
into diverse lineages, we developed a novel mammary tumor model in which oncogenic
Kras expression is initiated in luminal epithelial cells of the mammary gland. However,
the subsequent, continuous expression of KrasG12D is independent of a mammary
epithelial-specific promoter (Fig. 3.8A, left). We achieved this by generating females that
carry the WAP-Cre and TetO-KrasG12D transgenes along with a tTA knockin into the
endogenous Eef1a1 locus (EF1-LSL-tTA). The WAP-Cre mouse, established by Wagner
et al.123, expresses Cre recombinase under the control of the milk protein gene promoter
of the whey acidic protein (WAP). Since milk proteins are primarily synthesized in
luminal mammary epithelial cells during late pregnancy and lactation, transgenes that are
under the control of the WAP promoter are temporarily expressed during this time. In
fact, one round of pregnancy and lactation is sufficient to temporarily induce a WAPmediated expression of Cre recombinase, particularly in luminal lobuloalveolar cells that
undergo functional differentiation82. While hormonal stimuli influence the MMTV-LTR,
WAP promoter activity is tightly controlled by lactogenic hormones and thus targeted to
the luminal mammary compartment to an even greater extent. Therefore, with the WAP-
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Cre transgene, we have the necessary tool to target the Cre recombinase specifically to
luminal mammary epithelial cells. However, to conditionally express oncogenic Kras
without restricting the cell fate, it was necessary to develop a mechanism by which the
tTA is driven from a ubiquitously and continuously active promoter after initial activation
in the luminal compartment. For this purpose, we developed a new mouse model that
relies on the WAP-driven Cre recombinase for initial activation through the excision of a
transcriptional Stop sequence (loxP-Stop-loxP [LSL]) located between the Eef1a1
promoter and the tTA coding sequence. Once activated, the tTA is expressed under the
control of the ubiquitously active Eef1a1 gene promoter.
To develop this novel EF1-LSL-tTA knockin mouse model, we used an
established homologous recombination approach in mouse embryonic stem cells (ES) to
target the insertion of the tTA into the endogenous eukaryotic translation elongation
factor 1 alpha 1 (Eef1a1, EF1) locus (Fig. 3.1). EF1 is a crucial, ubiquitously expressed
housekeeping gene and its protein product is the second most abundant cytosolic protein
in the cell154. For the tTA to be conditionally activatable, the tTA is preceded by a
transcriptional Stop sequence, which is surrounded by two loxP sites (LSL). The Stop
sequence comprises three polyA signals, which prevents successful transcription of tTA
as long as the Stop sequence is present. The targeting vector (Fig. 3.6A) contains a few
other unique features that allow for more efficient screening of the successfully
transformed ES cells: a promoter-less neomycin selection marker that confers resistance
to Geneticin upon successful targeting, and a relatively short 3’ homology sequence that
allowed for PCR-based screening with primers that bind inside and outside of the Eef1a1
targeted region (Fig. 3.6B). Random integration events were avoided by strategically
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placing a splice acceptor site (SA) in front of the LSL sequence, which mediates the
expression of the neomycin resistance gene under the endogenous EF1 promoter, and
once the LSL and selection marker sequence is excised, facilitates the EF1-driven
expression of the tTA. To introduce the targeting vector into the ES cells, we
electroporated the linearized vector into S1B6a ES cells and selected them for neomycin
resistance.
PCR-based prescreening of 36 ES clones revealed that 27 of them (75%) had the
correct targeted insertion of the EF1-LSL-tTA construct, which was confirmed by EcoRV
restriction digest and Southern blot using a 5′ external probe that was not part of the
targeting vector (Fig. 3.6B). Since EF1 is an essential gene for cell survival, all successful
knockins are heterozygous because the insertion of the SA and LSL-tTA in front of the
first coding exon resulted in a functional Eef1a1 null allele, which would be lethal in a
homozygous configuration. This heterozygosity was confirmed in all eight screened
clones, where the Southern blot results showed the expected 3.85kb band for the targeted
EF1-LSL-tTA locus in addition to the 5.5 kb band for the wildtype Eef1a1 allele (Fig.
3.6C, representative blot). For successful targeting, we needed to use pure 129/Sv or
hybrid ES cells, as these lines were isogenic to the source DNA that was used for the
construction of the targeting vector homology arms. ES cells with the correct knockin
were injected into C57Bl/6J albino blastocyst and transferred to ICR pseudopregnant
females, which resulted in abundant offspring that displayed 40-90% chimerism. Males
from this offspring were crossed with C57Black Swiss females to transmit the EF1-LSLtTA knockin allele through the germline. To confirm that we obtained offspring with the
correct knockin, we completed several PCR-based validation experiments (Fig. 3.6B/D).
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Primer pairs 2452/2132 and 2453/2454 were used to confirm the presence of the 5’ and
3’ end of the inserted transgene, respectively. Primer pair 2452/2454 acts as a positive
control as it amplifies the wild type allele. We observed the presence of the wildtype
allele in all samples, further confirming that the EF1-LSL-tTA knockin can only occur in
a heterozygous configuration. Because the activity of tTA ultimately depends on the
successful excision of the transcriptional Stop sequence, we expressed Cre recombinase
in fibroblasts, derived from EF1-LSL-tTA transgenics and controls. Cre recombinase
excises DNA sequences located between two unidirectional loxP sites that are positioned
on the same linear DNA segment and consequently leave one loxP site behind (Fig.
3.6B). With the primer pair 2452/599, we confirmed that expression of Cre recombinase
was indeed leading to the excision of the transcriptional Stop sequence (Fig. 3.6D). The
heterozygous knockin did not cause any phenotypic abnormalities and did not affect
fertility in males or females. These observations held true, independent of the genetic
background of the mice, which we confirmed by backcrossing the EF1-LSL-tTA target
allele for more than ten generations into pure FVB/N or C57BL/6 backgrounds. Single
transgenic EF1-LSL-tTA mice are, therefore, not capable of tumor formation on their
own.
Next, we aimed at testing our newly developed EF1-LSL-tTA model in a
biologically relevant context. For the purpose of this study, it was vital that we could
target the activation of the tTA to a specific cell type and that the subsequent tTAmediated oncogene activation was continuously upheld. Previous attempts at fulfilling
these requirements have failed. While WAP-rtTA knockin mice are capable of expressing
TetO-driven responder transgenes in the presence of Doxycycline in specific cells of the
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mammary epithelium (alveolar cells) during late pregnancy and lactation, the problem
with this model is that the WAP promoter is only temporarily active during this time and
continuous activation of the responder transgene can therefore not be upheld155. We
consequently decided to evaluate if the tTA under control of the Eef1a1 locus is generally
suitable to direct the expression of transgenes to particular epithelial subtypes within a
defined developmental window and uphold the expression beyond this window. For this
purpose, we crossed the EF1-LSL-tTA knockin mice that carry luciferase or GFP reporter
transgenes with WAP-Cre mice (Fig. 3.7A). As discussed earlier, a single round of
pregnancy and lactation was found to be sufficient to activate WAP-mediated Cre
recombinase expression, specifically in functionally differentiated alveolar cells, which
belong to the luminal lineage. The lack of bioluminescent signals was therefore not
surprising in mammary glands of nulliparous WAP-Cre EF1-LSL-tTA TetO-Luciferase
triple transgenic females (not shown). However, activation of WAP-Cre during the first
pregnancy/lactation cycle led mammary-gland-specific and robust expression of
luciferase (Fig. 3.7B). Treatment with Doxycycline through the drinking water was
sufficient to eliminate the EF1-tTA-mediated activation of luciferase within 48 to 72
hours (Fig. 3.7C, left and center), and the withdrawal of Dox from lactating females
resulted in reactivation of luciferase expression within 7 to 14 days (Fig. 3.7C, right).
More importantly, robust luciferase expression levels were still detected beyond the
weaning of the offspring when the mammary gland undergoes extensive post-lactational
remodeling (involution). Immunofluorescence staining of mammary glands from WAPCre EF1-LSL-tTA TetO-H2B-GFP triple transgenic females with CK8, CK14, and GFP
confirmed that nuclear GFP expressing cells are exclusively found in the CK8-positive
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luminal compartment (Fig. 3.7D, left). The absence of nuclear GFP staining in CK14positive cells during lactation and beyond verifies the specificity of WAP-Cre-mediated
activation of EF1-tTA. The scattered presence of GFP-positive nuclei in alveolar cells
during lactation is likely a consequence of the combined mosaic expression patterns of
the WAP-Cre and TetO-H2B-GFP transgenes. However, the most critical finding was
that completely involuted (remodeled mammary gland to pre-pregnancy state) mammary
glands still showed luminal cells with EF1-tTA-mediated, constitutive expression of
nuclear GFP (Fig. 3.7D, right). We have previously described these functionally
differentiated, lobuloalveolar cells that survive the involution process82 and have shown
that they remain present over the lifespan of parous females following their first gestation
cycle92. It is important to note here that these cells are not long-term label-retaining
cells155, which indicates that the EF1-mediated expression of tTA and consequent
responder transgene activation is a constitutive process.
Based on these findings, we can conclude that the EF1-LSL-tTA mouse model allows for
cell-type-specific activation and constitutive activation of TetO-driven responder
transgenes, making it an excellent model to drive the conditional expression of
oncogenes.
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Figure 3.5 Expression of oncogenic KRAS tethered to the epithelial-specific MMTVLTR promoter likely restricts cell fate to the luminal lineage
Schematic model of cellular plasticity of MMTV-tTA-driven expression of oncogenic
KRAS. Green cells represent GFP-expressing cells that are able to transdifferentiate
within the expression limits of the MMTV promoter (grey box) but likely not beyond due
to negative selection when the cells are ablated of the driver oncogene, which they are
dependent on in vivo. Figure was created with Biorender.com.
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Figure 3.6 Targeted insertion of the LSL-tTA into the endogenous Eef1a1 (EF1)
locus
A. Schematic of the two-step cloning approach of the EF1-LSL-tTA gene targeting
vector. B. Approach for the homologous recombination-mediated, targeted knockin of the
LSL-tTA upstream of the first coding exon of the EF1 gene. C. Representative southern
blot analysis based on an EcoRV restriction digest in combination with a 3′ external
probe to verify the correct targeted insertion of the LSL-tTA. D. PCR-based genotyping
of genomic DNA derived from Eef1a1-LSL-tTA/+ mouse fibroblast with and without
Cre recombinase and a wildtype control (Eef1a1+/+). Abbreviations: ATG, start codon;
bGH, bovine growth hormone; L, loxP site; MSC, multi-cloning site; Neo, neomycin
selection marker; pA, polyadenylation signal; S, transcriptional Stop sequence; SA, splice
acceptor site; tTA, tetracycline-controlled transactivator. Arrows indicate primer
sequence locations. Note: This figure was previously published by Sakamoto and Rädler
et al.121.
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Figure 3.7 WAP-Cre-mediated, constitutive activation of EF1-tTA for temporally
and spatially controlled expression of effector transgenes in the developing
mammary gland
A. Schematic outline of the transgenes of the parity-induced, WAP-Cre-based mouse
model that facilitates constitutive activation of the EF1-LSL-tTA and its responder genes
exclusively in the mammary gland epithelium. B. In vivo bioluminescence imaging on
day 10 of lactation of a WAP-Cre EF1-LSL-tTA TetO-Luc triple transgenic female and a
littermate control without the WAP-Cre. C. In vivo bioluminescence imaging of two
triple transgenic females at lactation day 10 before (left) and during doxycycline (Dox)mediated suppression of luciferase activation (middle) and two weeks after
Dox-withdrawal (right). D. Immunofluorescence co-staining of H2B-GFP and
cytokeratin 8 (CK8) or cytokeratin 14 (CK14) on tissue sections of lactating mammary
glands (left and middle) and two weeks after the involution process (right); DAPI was
used as counterstain; bars represent 50 μm; yellow arrow indicates a typical spindleshaped nucleus of a myoepithelial cell. Note: This figure was previously published by
Sakamoto and Rädler et al.121.
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3.4 Luminal epithelial cell-specific activation of oncogenic RAS under the control of
a ubiquitously active promoter leads to the development of highly metastatic,
claudin-low mammary cancer
We subsequently integrated the newly developed EF1-tTA strain into the WAP-Cre
TetO-KrasG12D-carrying model to develop a triple transgenic model where oncogenic
KRAS expression is untethered from a mammary epithelial-specific promoter (Fig. 3.8A,
left). After the successful generation of females that carry all desired transgenes, we
observed that the development of mammary tumors of triple transgenic WAP-Cre EF1LSL-tTA TetO-KrasG12D females was dependent on their parity status (Fig. 3.8A, right).
Age-matched control females that were maintained as virgins (nulliparous) never
developed any observable mammary tumors, while females who had at least one fullterm pregnancy developed mammary tumors after a mean latency of 226 ±73 days.
Taking into consideration that it took approximately ten weeks until female mice
experienced their first full-term pregnancy (primiparous), the time of tumor onset after
initial initiation of oncogenic KRAS expression in these mice’s mammary glands is
comparable to MMTV-tTA TetO-KrasG12D females. Despite similar tumor latency in both
models, histopathological analysis of the WAP-Cre EF1-LSL-tTA TetO-KrasG12D
mammary tumors revealed substantial differences between them. Most WAP-Cre EF1LSL-tTA TetO-KrasG12D females developed EMT-type, spindle cell tumors, or mixed
tumors that were comprised of poorly differentiated adenocarcinomas with large amounts
of spindle-shaped cells (Fig. 3.8B, I and II). This contrasts with mammary tumors arising
from MMTV-tTA TetO-KrasG12D females, where the majority of tumors were not
comprised of cancer cells with spindle cell, EMT-type features. While EMT-type, spindle
cell mammary tumors were histologically predominant in the WAP-Cre EF1-LSL-tTA
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TetO-KrasG12D model, one tumor was determined to be a small cell adenocarcinoma (Fig.
3.8B, III). Orthotopic transplantation of mammary tumor fragments or isolated cancer
cells into wild-type females led to secondary tumor development within less than two
weeks. Without exception, all transplant recipient females developed mammary tumors
with spindle-shaped cancer cells (Fig. 3.8B, IV), and GFP positive pulmonary metastases
were detected in 92% of females at the time of necropsy (Fig. 3.8C). The use of the
CAG-LSL-GFP reporter transgene allowed us to easily detect macroscopic and even
microscopic metastatic lesions in the lung (Fig. 3.8D, left). These microscopic lung
metastases, as well as the GFP-positive macroscopic lung metastases, were comprised of
spindle-shape cancer cells (Fig. 3.8D, right).
Despite the expression of the same oncogenic driver in both mammary tumor
models, EF1-tTA driven expression of KrasG12D led to tumors that were
histopathologically different from the luminal-type cancers that arise in MMTV-tTA
TetO-KrasG12D females. Microarray-based gene expression profiling of WAP-Cre EF1LSL-tTA TetO-KrasG12D mammary tumors confirmed that the two models are also
molecularly distinct. Unsupervised hierarchical clustering of the gene expression data and
reference models revealed that EF1-tTA-driven expression of KrasG12D led to the
formation of mammary tumors that exclusively cluster to the claudin-low intrinsic
subtype (Fig. 3.3, red arrows). These tumors are, therefore, molecularly and
histopathologically distinct from most cancers that arise from the MMTV-tTA-driven
model. Immunoblot analysis showed that mutant KRAS protein levels are similar in
mammary tumors of both models (Fig. 3.9A), demonstrating that the histopathological
and molecular differences are not due to increased EF1-tTA mediated transactivation of
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TetO-KrasG12D. Overall, this data suggests that uncoupling the expression of mutant Kras
from an epithelial-cell-specific promoter after initial pregnancy-induced activation of
expression leads to the development of claudin-low mammary cancers. Interestingly, we
noticed that the claudin-low mammary tumors of the EF1-tTA-driven model consistently
showed molecular alterations in Cdkn2a and p53 (Fig. 3.9B/C). Transcriptional
repression of Cdkn2a in these mammary tumors led to a concordant loss of p19Arf and
p16Ink4a protein expression. Both of these proteins function as tumor suppressors, and
particularly ARF has been shown to be upregulated in the presence of oncogenic
hyperproliferative signals156,157. While p16Ink4a binds to CDK4 and CDK6 to suppress cell
cycle progression, p19Arf prevents the degradation of p53, which itself functions as a
tumor suppressor. In some cases, we also observed additional sporadic mutations in
Trp53, which are known to increase p53 protein levels but disrupt tumor-suppressive
functions158. Mutations in the p53 gene are also widespread in human cancer cell lines
that were classified as claudin-low by Prat et al.54. In fact, all seven human claudin-low
breast cancer cell lines in this study have mutations in TP53. Interestingly, the human
claudin-low breast cancer cell line, MDA-MB-231, has mutations in CDKN2A and TP53
(information obtained from COSMIC). Based on these observations, our EF1-tTA-driven
oncogenic KRAS expression model seems to recapitulate major features that are
observed in human claudin-low cancer cells.
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Figure 3.8 Constitutively active expression of oncogenic KRAS in luminal epithelial
cells under the control of the lineage-independent EF1 locus-driven tTA results in
the development of claudin-low mammary cancer
A. Schematic outline of the transgenes (left) and Kaplan-Meier survival curve (right) of
mice that express constitutively active and doxycycline (Dox)-repressible oncogenic
KRAS in functionally differentiated (i.e., WAP-Cre expression) luminal alveolar cells
upon a full-term pregnancy. Co-activation of GFP under the control of the chicken betaactin gene (CAG) promoter following WAP-Cre mediated recombination serves as
genetic cell lineage tracing tool during cancer progression. B. H&E staining of primary
mammary tumor tissue sections (I-III) and established secondary tumor from a WAP-Cre
EF1-tTA TetO-KrasG12D tumor-fragment transplant (IV); bars represent 200 μm. C.
Pulmonary metastasis frequency in tumor-bearing, wild type recipients that were
orthotopically transplanted with tumor fragments that express oncogenic KRAS under the
control of the EF1-tTA. D. Brightfield and GFP stereoscope images and corresponding
histopathological sections of lungs from tumor-bearing recipient mice; bars represent
2mm and 50 μm, respectively.
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Figure 3.9 Immunoblot-based comparative analysis of KRAS expression,
downstream activation of the mitogen-activated protein (MAP) kinase ERK, and
expression of Cdkn2/p53 pathway constituents in mammary tumors that express
oncogenic KRAS under control of the MMTV-LTR or constitutively active EF1
promoter
A. Immunoblot analysis of KRAS, phosphorylated ERK, and ERBB2/neu on mammary
tumors that overexpress ERBB2 (MMTV-neu) or oncogenic KRAS under control of the
MMTV-tTA or the WAP-Cre-initiated EF1-tTA; GAPDH serves as loading control.
B. Immunoblot analysis of p53, MDM2, and p19Arf/p16Ink4a in claudin-low mammary
tumors that originated in WAP-Cre EF1-LSL-tTA TetO-KrasG12D transgenic females in
comparison to control cells that lack expression of Cdkn2a (NIH3T3) or p53 (p53-/mouse embryonic fibroblasts, MEFs ), or mammary epithelial cells that possess a known
mutation in p53 (HC11). C. Immunoblot analysis of p53 and p19Arf/p16Ink4a expression in
the mammary tumor samples displayed in panel A.
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3.5 The development of claudin-low mammary tumors is a gradual process that
involves an initial luminal-to-basal-epithelial transition
Because the WAP-Cre EF1-LSL-tTA TetO-KrasG12D mammary tumors clustered to the
claudin-low mammary tumor subtype, we were interested in the process of how this
subtype arises from luminal epithelial mammary cells. To understand this process, it is
important to know that the post-lactational mammary gland undergoes extensive
apoptosis in a process called involution. During this time, many milk-producing cells
undergo cell death. However, with the help of Cre/lox-based cell-lineage tracing, we have
previously shown that a subset of functionally differentiating epithelial cells that
expressed the WAP-Cre transgene during pregnancy and lactation are retained within the
mammary glands of parous females82. These remaining, parity-induced mammary
epithelial cells (PI-MECs) function as alveolar progenitors, giving rise to new alveolar
cells during subsequent pregnancies. PI-MECs belong to the luminal-lineage of the
mammary epithelium, and we confirmed that they are distinct from CK14-positive basal
epithelial cells (Fig. 3.10A, left). WAP-Cre mediated initiation of EF1-tTA activation,
therefore, occurs in luminal-type PI-MECs.
The MMTV-tTA and the EF1-tTA-based mammary cancer model have in
common that in the untransformed adult mammary gland, the expression dominantly
occurs in luminal epithelial cells. Particularly, the initial WAP-Cre-driven activation of
EF1-tTA never occurred outside of the luminal compartment. However, the mode in
which tTA and oncogenic KRAS are expressed are fundamentally different between the
two models. While the MMTV-mediated expression of the tTA and oncogenic KRAS
seems to depend on the cell’s differentiation state, the EF1-tTA-based model allows for
constitutive expression of tTA and oncogenic KRAS in neoplastic cells independent of
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the cellular differentiation state as EF1-promoter activity is not differentiation-statedependent. This uncoupling of oncogene expression from a mammary-epithelial cell fate
allows the cells to assume diverse developmental states.
WAP-Cre-mediated activation of the reporter transgene CAG-LSL-GFP in our
quadruple transgenic WAP-Cre; EF1-LSL-tTA; TetO-KrasG12D; CAG-LSL-GFP females
served as evidence that constitutive expression of oncogenic KRAS in PI-MECs initially
led to the transformation of PI-MECs into preneoplastic lesions (Fig. 3.10A, right). These
lesions progressed into GFP-positive mammary tumors, which gradually gained invasive,
EMT-like features and assumed a mesenchymal phenotype (Fig. 3.10B). In the initial
stages of mammary cancer development, oncogenic KRAS expression caused a numeric
expansion of CK8-positive PI-MECs within focal regions of the mammary glands (Fig.
3.11 A, top). What was remarkable about this expanding population was that isolated
cells with typical luminal-like histology started to co-express the basal lineage marker
CK14. Dual staining of CK8 and CK14 typically does not occur in PI-MECs or other
known luminal-lineage subpopulations in adult mammary glands, especially not in cells
that are luminal in appearance. As the neoplastic transformation progressed, we observed
that groups of dual-positive cells filled the lumen, similar in appearance to ductal
carcinomas in situ (DCIS). These cells then gradually developed into basal-like
preneoplastic lesions (Fig. 3.10A, right), which subsequently progressed into mammary
tumors that were predominately comprised of CK14-positive cancer cells and lacked the
expression of the luminal lineage marker CK8 (Fig. 3.11A, middle left). High expression
of CK14 and other basal lineage markers such as CK5 and CK6 is a typical characteristic
of basal-like mammary tumors and is not a feature of the claudin-low subtype. However,
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we discovered that these tumors subsequently assumed mesenchymal features,
characteristic of claudin-low mammary cancers. Concordant with the claudin-low
subtype, staining of these tumors and their metastatic descendants revealed that CK14
was significantly reduced or completely lost (Fig. 3.11A, middle right, and bottom; Fig.
3.10C). CK8 was completely absent in these tissues as well. The epithelial to
mesenchymal transition (EMT) is often characterized by the expression of E-cadherin
and N-cadherin. Normal luminal mammary epithelial cells express E-cadherin but are
negative for N-cadherin. During the epithelial to mesenchymal transition, epithelial cells
gradually lose E-cadherin expression and, at the same time, gain expression of Ncadherin159. To identify at what time point EMT is initiated in our mammary tumors, we
stained tissue sections from different tumor progression stages. Surprisingly, we observed
that the mesenchymal transition already started during the early stages of neoplastic
progression in cells that appeared luminal-like. These preneoplastic lesions were
comprised of groups of cells that showed N-cadherin expression and filled the lumen of
the mammary ducts but had not yet escaped the epithelial phenotype (Fig. 3.11B, left). As
the cancers progressed into tumors, they exhibited a heterogeneous phenotype, where
cancer cells within the tumor stained E-cadherin or N-cadherin positive (Fig. 3.11B,
middle). During this stage, E-cadherin expression already appeared to weaken in certain
areas, and once the growing tumors had reached their mesenchymal state, these claudinlow mammary tumors were predominantly negative for E-cadherin but positive for Ncadherin (Fig. 3.11B, right).
A previous publication has suggested that the claudin-low subtype might be an
artifact due to a significant abundance of tumor-infiltrating stromal cells, which are

102

histopathologically virtually indistinguishable from mesenchymal cancer cells160.
However, we show that the cells that comprise our claudin-low mammary tumors and
their metastatic descendants have sustained GFP expression (Fig. 3.10B), demonstrating
that these mesenchymal-like cells originated from PI-MECs in the epithelial mammary
compartment and are therefore not tumor-associated fibroblasts. Thus, we have
established that the EF1-tTA-mediated oncogenic KRAS expression in luminal PI-MECs
leads to the development of claudin-low mammary cancers by initially transitioning from
a luminal to a basal-like state and finally into the claudin-low subtype. We attribute this
freedom of cells to transition from a functionally-differentiated luminal state to an
undifferentiated mesenchymal state to the EF1-tTA-mediated and differentiation-stateindependent expression of oncogenic KRAS.
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Figure 3.10 Cre/lox-based cell lineage tracing shows that preneoplastic lesions,
mammary tumors with epithelial and mesenchymal appearance, as well as
pulmonary metastatic lesions arise in response to oncogenic KRAS in luminal cells
within terminal ducts and alveolar units that had expressed the WAP-Cre
transgene.
A. Co-immunofluorescent staining of GFP and cytokeratin 14 (CK14) in mammary gland
tissue sections from nonpregnant, parous WAP-Cre CAG-LSL-GFP transgenic control
female (left) and a small hyperplastic lesion in the mammary gland of a parous WAP-Cre
CAG-LSL-GFP EF1-LSL-tTA TetO-KrasG12D quadruple transgenic female (right); bars
represent 50 μm; DAPI is the counterstain. B. Immunofluorescent staining of GFP in
tissue sections of mammary tumors from WAP-Cre CAG-LSL-GFP EF1-LSL-tTA TetOKrasG12D transgenic females. C. Co-immunofluorescent staining of GFP and CK14 in
pulmonary metastatic lesions of claudin-low mammary tumors from quadruple transgenic
WAP-Cre CAG-LSL-GFP EF1-LSL-tTA TetO-KrasG12D females.
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Figure 3.11 Transdifferentiation into the mesenchymal differentiation state is
preceded by a luminal-to-basal transdifferentiation in mammary cancers that
express oncogenic KRAS under control of the constitutively active EF1-tTA
A. Co-immunofluorescent staining of cytokeratins 8 and 14 (CK8, CK14) in
preneoplastic lesions (top), mammary tumors (middle), and pulmonary metastases
(bottom) of parous WAP-Cre EF1-tTA TetO-KrasG12D transgenic females. B. Coimmunofluorescent staining of E- and N-Cadherin in preneoplastic lesions (left) and
mammary tumors (middle and right); bars in panels A and B represent 50 μm.
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3.6 Activation of mutant KRAS from its endogenous locus causes the development of
aggressive basal-like and claudin-low mammary cancers
Both, the MMTV-tTA-based and the EF1-tTA-based model, express exogenous
oncogenic KRAS. To exclude the possibility that claudin-low mammary tumor
development is an artifact of exogenous oncogene expression, we established a third
mouse model that allows for the inducible expression of oncogenic KRAS from its
endogenous promoter in the mammary epithelium. Previously developed mouse models
that express oncogenic Kras from its endogenous locus are not ideal for studying
mammary tumor development due to the onset of other malignancies before mammary
tumors could arise161. Attempts to conditionally activate a KrasG12D allele in the
mammary epithelium via MMTV-Cre also proved to be problematic as these mice
developed salivary hyperplasia162. We, therefore, developed a new mammary tumor
mouse model where oncogenic KRAS is expressed from its endogenous genomic locus
upon Flp recombinase-mediated activation (Fig. 3.12). The Flp recombinase itself is
under the control of the 2.4kb MMTV-LTR in this model, conferring more stringent
specificity to the epithelium of the mammary gland than previously established models
that make use of the shorter MMTV-LTR. Because the MMTV-tTA and the MMTV-Flp
strain make use of the identical MMTV-LTR construct, we postulated that the Flp
recombinase would also be predominately expressed in the luminal epithelial
compartment of female mammary glands. To experimentally confirm this, we generated a
double transgenic mouse strain that carries the MMTV-Flp transgene and the reporter
transgene ROSA26CAG-FSF-GFP. Flp recombinase functions based on the same principle as
Cre recombinase, but instead of loxP sites, the Flp recombinase detects frt sites.
Consequently, in the presence of Flp recombinase, the transcriptional Stop sequence of
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the frt-Stop-frt (FSF) construct is removed, which leads to the expression of GFP under
the control of the constitutively active CAG promoter in these double transgenic mice.
Staining of adult mammary glands with GFP, CK8, and CK14 confirmed that MMTVFlp is predominately active in the luminal epithelium of these mammary glands (Fig.
3.13). To activate KrasG12D in an endogenous manner in the luminal epithelium of the
mammary gland, we obtained the previously described Flp-inducible KrasG12D knockin
strain FSF-KrasG12D from The Jackson Laboratory and crossed these mice with mice that
carry the MMTV-Flp transgene. Because p53 pathway alterations are common in
claudin-low mammary cancers, we additionally introduced a single allele of mutant p53
(p53R172H) into our model to generate the triple transgenic MMTV-Flp FSF-KrasG12D
p53R172H strain. In this strain, active Flp recombinase in the mammary epithelium induces
KrasG12D expression by removing the transcriptional Stop sequence between the
endogenous Kras promoter and the mutant Kras knockin. All mutant Kras knockin mice
are heterozygous since the knockin allele is a functional null allele prior to Flp
recombinase-mediated activation. Because KRAS expression is essential, a homozygous
knockin is not viable.
Expression of mutant KRAS resulted in mammary cancer development in our
triple transgenic females at a mean latency of 97 days (Fig. 3.14A). Single transgenic
littermate controls never developed mammary tumors within one year of age.
Histopathological analysis of the mammary tumors revealed that the activation of
endogenous mutant KRAS resulted in EMT-like, spindle cell tumors, and poorly
differentiated adenocarcinomas (Fig. 3.14B, I and II). In light of the relatively short
tumor onset, it was surprising to find metastases in the lung in a subset of females (Fig.
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3.14B, III), which speaks for the tumors’ highly metastatic capabilities. To confirm that
these tumors were the result of Flp-mediated activation of the endogenous mutant
KrasG12D allele, we performed a PCR based assay on a total of six mammary tumors (Fig.
3.14C, top), where half were characterized as EMT-like spindle cell tumors (tumors 1-3),
and the other three were characterized as basal-like poorly differentiated
adenocarcinomas (tumors 4-6). To our surprise, two of the three EMT-like mammary
tumors (i.e., tumor samples 2 and 3) had lost the wildtype Kas allele, while all other
tumor samples maintained their wildtype allele and showed the anticipated activation of
the endogenous mutant allele. Corresponding immunoblot analysis revealed elevated
KRAS protein levels in the two tumors that only expressed the KRAS mutant allele (Fig.
3.14C, bottom). Another important observation of this analysis was that KRAS protein
levels in mammary tumors from the EF1-tTA-based model (tumors a-c) were similar to
those that express KrasG12D from the endogenous locus. The level of KRAS protein
expression is, therefore, independent of the oncogene expression mode. Our findings
indicate that cancer cells are likely subject to a selective process in which biologically
relevant levels of oncogenic KRAS are selected for to promote optimal tumor-initiation
and progression. The concept that oncogenes express at a level that is “just right” in
cancer cells has been explored previously in other cancers and suggests that too much
oncogenic signaling can be as unfavorable as too little163. Probing for phosphorylation of
ERK1/2 in mammary tumors of all three models also revealed that the downstream
activation of these MAP kinases does not always correlate with the amount of mutant
KRAS protein present within individual tumors (Fig. 3.14C, bottom; Fig. 3.9A).
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After we had established that endogenous and exogenous expression of KrasG12D
results in similar KRAS protein expression levels, we set out to identify the molecular
subtype of mammary tumors that express oncogenic KRAS from the endogenous locus.
For this purpose, we sequenced the RNA of 10 primary mammary tumors, which
included five tumors for each of the two histological subtypes that we observed. The
resulting gene expression data was clustered via unsupervised hierarchical clustering to
mouse mammary tumor reference gene expression data derived from a broad spectrum of
mammary cancer models. Mammary tumors that were histologically classified as poorly
differentiated adenocarcinomas showed molecular features of the basal-like subtype (Fig.
3.14D, yellow). EMT-like, spindle-shaped tumors, on the other hand, clustered to the
claudin-low reference mouse models (blue) and showed particular molecular consistency
in gene clusters that are characteristically low in claudin-low tumors (Fig. 3.14, pink). A
major factor that distinguishes basal-like and claudin-low mammary tumors is the
expression of basal lineage markers and cell adhesion molecules such as EPCAM and Ncadherin. Unsupervised hierarchical clustering based on Krt5 (CK5), Krt6a and Krt6b
(CK6), Epcam, and Cdh2 (N-cadherin) gene expression nicely separated the ten
mammary tumors into the basal-like and claudin-low mammary tumor subtypes (Fig.
3.14D, bottom). This pattern of gene expression was also recapitulated on the protein
level. Immunoblot analysis of the six mammary tumors that arose from the endogenous
expression of KrasG12D validated that basal-like cancers express the cell adhesion
molecules EpCAM and E-cadherin, as well as the basal lineage marker CK14, but lack
the expression of N-cadherin (Fig. 3.14E). The three claudin-low mammary tumors, on
the other hand, showed expression of N-cadherin but mostly lacked all other markers,
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which is consistent with the expression pattern of these markers in claudin-low mammary
tumors from the EF1-tTA-based transgenic females. Additional comparison of the two
distinct histological and molecular subtypes by immunofluorescence staining confirmed
that basal-like tumors express the basal lineage markers CK14, CK5, and CK6 but lacked
the expression of CK8 (Fig. 3.14F, top; Fig. 3.16A). As anticipated, claudin-low
mammary tumors lacked the protein expression of these markers. The expression pattern
of N-cadherin and E-cadherin that we observed by immunoblot was also confirmed in
mammary tumor sections (Fig. 3.14F, bottom). Prat et al.54 have previously reported that
claudin-low mammary tumors show reduced Ki67 expression compared to basal-like
mammary cancers, which is why we stained mammary tumors of both molecular
subtypes arising from the MMTV-Flp FSF-KrasG12D p53R172H strain for Ki67 (Fig.
3.16B). Indeed, claudin-low mammary tumors showed significantly reduced Ki67
expression in comparison to basal-like mammary tumors.
Since we had observed loss of Cdkn2a expression and concurrent loss of p19Arf in
claudin-low mammary tumors of the EF1-tTA-based strain, we were interested to see if
similar alterations occur in the mammary tumors that were initiated through activation of
endogenous KrasG12D in the presence of mutant p53. Interestingly these tumors retained
the expression of p19Arf, suggesting that the functional loss of Cdkn2a might precede
mutational changes in p53 wildtype cells (Fig. 3.17A/B). Other studies have observed
similar events where Cdkn2a was homozygously silenced in the presence of the
oncogenic driver KRAS to allow the pathogenesis from B-cells into precursor B-cell
acute lymphoblastic leukemia164. Genetic alterations in Trp53 and Cdkn2a are not
mutually exclusive in claudin-low mammary tumors as both, the EF1-tTA-based model
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as well as four of the seven human claudin-low breast cancer cell lines, show alterations
in both genes. Among these four human claudin-low cell lines, three (Hs578T, MDAMB-231, and SUM159PT) carry mutations in RAS.
The collective results from this line of investigation demonstrate that oncogenic
KRAS expression exists at biologically relevant levels and does not differ considerably
between endogenous and exogenous expression. We further validated that endogenous
oncogenic RAS signaling leads to the development of basal-like and claudin-low
mammary cancers and is likely supported by alterations in the tumor suppressor genes
Cdkn2a and/or Trp53.
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Figure 3.12 Expression of a gain-of-function mutant Kras from its endogenous locus
targeted to the mammary epithelium
Schematic outline of the transgenes of mice that express oncogenic KRAS from its
endogenous locus upon MMTV-Flp-mediated activation of the mutant allele in the
mammary gland epithelium. These mice also carry a heterozygous germline mutation in
Trp53 (gene of p53), resulting in the MMTV-Flp FSF-KrasG12D p53R172H triple transgenic
mouse model.
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Figure 3.13 The MMTV-Flp transgene is expressed in the luminal epithelium of the
mammary gland
Co-immunofluorescence staining of GFP and luminal cytokeratin 8 (CK8) or basal
cytokeratin 14 (CK14) in mammary gland sections of MMTV-Flp Rosa26CAG-FSF-GFP
female mice; bars represent 50 μm.
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Figure 3.14 A gain-of-function mutation of endogenous Kras in the mammary
epithelium results in the development of basal-like and claudin-low mammary
cancers
A. Kaplan-Meier survival curve of mice constitutively expressing KRASG12D from the
endogenous Kras gene locus in a Flp-recombinase-inducible manner in the presence of a
mutant p53R172H allele. B. H&E stained tissue sections of primary mammary tumors (I, II)
and a pulmonary metastatic lesion (III). C. Top panel: PCR-based validation of the Flpmediated excision of the Frt-Stop-Frt (FSF) sequence in the targeted FSF-KrasG12D
allele; S, DNA ladder: C1 and C2, tail DNA of mice that carry two wildtype Kras alleles
(C1) or one FSF-KrasG12D allele (C2); NC, no DNA control. Bottom panel:
Comparative immunoblot analysis of KRAS expression and activation of MAP kinases in
mammary tumors that originated in mice with exogenous mutant KRAS expression
(samples a-c) and mammary tumors expressing endogenous KRASG12D (samples 1-6
corresponding to top panel). Note that mice 1-6 carried one FSF-KrasG12D and one
wildtype Kras allele. Thus, the loss of the wildtype Kras allele in tumor samples 2 and 3
occurred somatically. D. Top panel: Unsupervised hierarchical clustering of RNAseqbased gene expression data to compare the molecular profiles of mammary tumors
expressing endogenous KrasG12D with reference sets from diverse mammary cancer
models. Bottom panel: Unsupervised hierarchical clustering based on the gene expression
of basal-type keratins (Krt5, Krt6a/b), Epam, and N-cadherin (Cdh2) between mutant
KRAS expressing tumors. E. Immunoblot analysis of E-cadherin, N-cadherin, EpCam,
and CK14 expression of the same mammary tumors as shown in panel C.
F. Co-immunofluorescence staining of CK8 and CK14, as well as E-cadherin and Ncadherin in sections from basal-like or claudin-low tumors; bars represent 50 μm.
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Figure 3.15 MMTV-Flp-mediated activation of an endogenous KrasG12D allele in the
mammary epithelium causes basal-like and claudin-low mammary cancers
Complete illustration of the results of the Unsupervised hierarchical clustering of
RNAseq-based gene expression data to compare the molecular profiles of mammary
tumors expressing endogenous KrasG12D with reference sets from diverse mammary
cancer models based on an intrinsic gene set.
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Figure 3.16 Basal-like and claudin-low mammary cancers that arise in female mice
expressing oncogenic KRASG12D from the endogenous Kras locus exhibit
characteristic differences in basal keratin, N-Cadherin, and cell proliferation
marker expression.
A. Co-immunofluorescence staining of N-cadherin and cytokeratins 5 (CK5) or
cytokeratin 6 (CK6) in tissue sections of basal-like and claudin-low mammary tumors
according to their gene expression clustering-based classification; bars represent 50 μm.
B. Co-immunofluorescence staining of the proliferation-marker Ki-67 and N-Cadherin,
and a graphical illustration of the difference in the relative number of Ki-67-positive
cancer cells on tissue sections of basal-like and claudin-low mammary tumors.
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Figure 3.17 Comparative analysis of Cdkn2 and p53 expression in claudin-low
mammary tumors that express exogenous or endogenous KRASG12D
A. Exome-based gene expression histograms of the Cdkn2a locus in mammary cancer
tissues from MMTV-Flp FSF-KrasG12D p53R172H females. B. Expression of p53 and
p19Arf protein in mammary tumors that originated in mice with exogenous KRASG12D
expression (samples a-c) and mice expressing endogenous KRASG12D (samples 1-6), and
control samples that are described in figure 3.9. Samples a-c and 1-3 exhibited claudinlow gene expression signatures and samples 4-6 are basal-like mammary tumors.
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Figure 3.17
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3.7 Persistent oncogenic RAS signaling cooperates with other molecular pathways to
control cellular plasticity
We have shown that the EF1-tTA-mediated expression of exogenous KrasG12D and the
expression of endogenous oncogenic KRAS in the luminal mammary epithelium result in
the development of basal-like and claudin-low mammary tumors. This observation
suggests that RAS signaling is a determinant for the genesis of these triple-negative
breast cancer subtypes. To evaluate the importance of continuous oncogenic RAS
signaling in claudin-low mammary tumors of the EF1-tTA-based model, we treated
tumor-bearing female mice with doxycycline (Dox), which prevents the tTA from
binding to the Tet-operon and concurrently terminates the expression of oncogenic Kras.
Subsequent regression of these mammary tumors indicates that in vivo claudin-low
mammary cancer cells are dependent on continuous expression of the transforming
oncogene for their proliferation and survival (Fig. 3.18A).
We and others have previously reported that pancreatic cancer cells that express
c-MYC or mutant KRAS in a ligand-controlled manner do not rely on the oncogenic
driver when maintained in cell culture165,166. To determine if this also holds true for
mammary cancer cell lines, we derived polyclonal mammary tumor cell lines from GFP
positive WAP-Cre EF1-tTA TetO-KrasG12D CAG-GFP claudin-low mammary tumors.
Subsequent treatment with Dox revealed that these cells were indeed capable of surviving
in cell culture independent of oncogenic KRAS expression (Fig. 3.18B). Since claudinlow mammary tumor-derived cell lines did not depend on the persistent expression of
KrasG12D for their survival, they provided a unique model system to determine if the
maintenance of the mesenchymal phenotype of claudin-low mammary cancer cells is
dependent on the persistent expression of oncogenic KRAS. Morphological changes of
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cultured WAP-Cre EF1-tTA TetO-KrasG12D CAG-GFP cancer cells were already
apparent after 48 to 96 hours of Dox treatment, accompanied by a significant reduction in
proliferation in comparison to untreated isogenic cell lines (Fig. 3.18B/C). Dox-treated
cells appeared to assume a more 2-dimensional epithelial-like phenotype where cells
were tightly packed next to each other, unlike their untreated isogenic cells, which
showed a mesenchymal phenotype with cells growing on top of each other. Continuous
GFP expression due to the Cre-activated CAG-GFP reporter gene confirmed that these
and all subsequent investigations were carried out on pure cancer cell lines. The presence
of GFP in Dox-treated cell lines, in particular, confirmed that the cells were indeed
morphologically transformed cancer cells. Immunoblot analysis confirmed the
conditional downregulation of oncogenic KRAS in the presence of Dox and concurrent
dephosphorylation of downstream MAP kinases (Fig. 3.18D). Reduced protein
expression of cleaved Caspase-3 in Dox-treated cells indicated that these cells did not
undergo apoptosis in the absence of oncogenic KRAS. The lack of mutant KRAS
signaling and consequent decreased oncogenic stress might explain this observation. To
characterize the molecular changes that are accompanied with the morphological changes
when mutant KRAS is ablated, we performed RNAseq on three of these Dox-treated
cancer cell lines and their isogenic untreated controls. The resulting gene expression data
was used to run a paired differential gene expression analysis. The difference between a
pooled and paired differential gene expression analysis is that the gene expression
differences are directly compared between the isogenic samples and checked for
consistency among all isogenic pairs in the paired analysis. By running this differential
expression analysis with highly conservative analysis parameters, we identified 1296
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genes that were downregulated and 1260 genes that exhibited an increase in their mRNA
expression when oncogenic RAS expression was turned off. Given the stringent cutoff
for significant gene deregulation, the number of differentially expressed genes suggests
oncogenic KRAS signaling ablation leads to drastic molecular changes. Besides the
anticipated gene expression differences in the RAS/MAPK signaling pathway, we
observed many well-known genes that are recognized to play important biological roles.
To characterize how these gene deregulations fit into the broader biological context, we
performed a gene set enrichment analysis (GSEA), which revealed the deregulation of
diverse biologically relevant pathways and processes such as the formation of focal
adhesions and stem cell signaling (Fig. 3.18 E). Other pathways, including RNA
biosynthesis, ECM-receptor interaction, as well as TGF-beta, HIPPO, Notch, TNF, and
WNT signaling, were shown to be enriched (not shown), meaning that a substantial
subset of genes that comprise these pathways/gene sets were significantly deregulated.
A closer look at the genes known to play a role in ECM signaling and focal adhesion
revealed a significant deregulation of genes that code for bonafide epithelial mammary
cell lineage marker proteins. Upregulation of Cd24a, Itgb3, and Gata3 combined with a
reduction of Itgb6 on the transcriptional level in cells lacking the oncogenic expression of
KRAS hinted at a molecular drift away from the undifferentiated mesenchymal state (Fig.
3.19A). Subsequently, we performed immunoblot and flow cytometry analyses and
confirmed that the gene expression changes are reproducible at the protein level. Many
claudin-low mammary tumor cells that express mutant KRAS showed high expression of
CD49f, low or no expression of CD24, and mostly lacked the expression of CD61(Itgb3)
and GATA3 (Fig. 3.19B/C). This expression pattern corresponds to an undifferentiated
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cell state as CD49f is considered a marker for mammary cancer stemness, and the other
three markers are typically expressed at moderate to high levels in normal luminal cells.
Ablation of oncogenic KRAS in these cells resulted in the upregulation of CD61 and
GATA3 (Fig. 3.19B; Fig. 3.19C, bottom), which are typically expressed in luminal
progenitors of the normal mammary epithelium78. We also observed a concurrent
reduction in CD49f expression and a substantial increase in cells that express high levels
of CD24 (Fig. 3.19C, top). CD24, encoded by Cd24a, is expressed at high levels in
normal luminal mammary epithelial cells and decreases according to the different cellular
differentiation states167. Based on these molecular changes, it became apparent that these
cells redifferentiated towards a more luminal epithelial fate upon suppression of
KRASG12D expression. This partial reversal of the transdifferentiation program supports
our findings that luminal epithelial cells give rise to claudin-low tumors when oncogenic
KRAS expression is driven by the EF1-tTA-based system. Although it seemed like
continuous oncogenic KRAS signaling is the main factor that maintained the claudin-low,
mesenchymal cell state, we did not observe a complete mesenchymal to epithelial
transition (MET) when mutant KRAS was ablated. Despite the gain of expression of the
luminal lineage markers GATA3, CD61, and CD24 in mutant KRAS deficient cells, Ecadherin was re-expressed in only a subset of cells, and N-cadherin expression remained
unchanged (Fig. 3.19D). Remarkably, when we examined other genes that are known to
play a relevant role in EMT/MET, we discovered that both Snai1 (SNAIL) and Snai2
(SLUG) were transcriptionally upregulated in cells that lacked oncogenic KRAS
expression. At the protein level, it was apparent that SNAIL remained relatively
consistent, but SLUG expression was substantially increased in all three Dox-treated cell
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lines (Fig. 3.19D). Previous findings by Bolós et al.102 demonstrate that the transcription
factor SLUG suppresses E-cadherin expression and induces EMT, which is also true for
SNAIL168. Since increased SLUG expression might contribute to the maintenance of
mesenchymal molecular features, we aimed to assess the biological roles of SLUG and its
closely related protein SNAIL. For this purpose, we generated shRNA-mediated SLUG
and SNAIL knockdowns in the claudin-low mammary cancer cells that conditionally
express mutant KRAS. Significantly reduced levels of SLUG resulted in an upregulation
or sustained expression of E-cadherin in two of the three cancer cell lines in the absence
of oncogenic KRAS signaling (Fig. 3.19E; Fig. 3.20A). Interestingly, cell line 1
displayed a co-dependency on RAS, SLUG, and SNAIL. In this cell line, SLUG
knockdown resulted in a concurrent decrease in SNAIL that, when knocked down
independently, was sufficient to upregulate the expression of E-cadherin in mutant
KRAS-ablated cells (Fig. 3.20B). Based on these findings, it is evident that cellular
plasticity is under the control of multifactorial mechanisms. While our results suggest
that SLUG and SNAIL can act synergistically with oncogenic RAS signaling to mediate
cellular plasticity, it must be true that other factors may facilitate cellular plasticity
independent of mutant KRAS signaling. This statement is supported by the continuously
maintained E-cadherin repression in claudin-low cell line 2, even when oncogenic
KRAS, SLUG, and SNAIL are absent. Despite significant increases in CD61, GATA3,
and CD24 in this cell line in the absence of oncogenic KRAS expression, mesenchymal
characteristics of claudin-low mammary cancers were maintained on the molecular level,
which suggests that additional molecular mechanisms may coordinate the maintenance of
mesenchymal features. Overall, we established that oncogenic RAS signaling cooperates
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with other molecular mechanisms to maintain the mesenchymal-like differentiation state
of claudin-low mammary cancer cells. While a complete reversal into a luminal epithelial
differentiation state did not occur, we nonetheless demonstrate that claudin-low cancer
cells maintained intrinsic cellular plasticity that allows the cells to acquire luminal
progenitor characteristics.
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Figure 3.18 Doxycycline-mediated suppression of oncogenic KRAS expression in
claudin-low mammary cancer cells results in substantial transcriptomic changes
A. Regression of mammary tumors in wildtype tumor-bearing mice that had prior to
treatment with doxycycline (Dox) for 18 days received orthotopic transplants of WAPCre EF1-LSL-tTA CAG-LSL-GFP TetO-KrasG12D mammary tumor cells, which
engrafted and established mammary tumors with a volume of about 400mm3. B. Cultured
mammary cancer cells derived from WAP-Cre EF1-LSL-tTA CAG-LSL-GFP TetOKrasG12D tumors, before and after treatment with Dox for 72 hrs. Insets show
corresponding GFP fluorescent images of the same cells; bars represent 100 µm. C.
Decrease in relative proliferation rates following the ablation of oncogenic KRAS with
Dox in the cell cultures shown in panel B. D. Comparative immunoblot analysis in three
independent cell cultures with and without Dox, examining the protein levels of KRAS,
activation of MAP kinases, and activation of cleaved Caspase-3; GAPDH served as
loading control. E. Gene Set Enrichment Analysis (GSEA) plots of selected pathways
and the corresponding significantly deregulated genes (FDR <0.05 and log2FC > 1.5)
within these pathways following the Dox-mediated suppression of oncogenic KRAS
portrayed as heat maps.
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Figure 3.18
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Figure 3.19 Oncogenic RAS signaling controls the cellular plasticity of claudin-low
mammary cancer cells
A. Boxplot and dotplot illustrating the changes in mRNA expression of genes defining
mammary epithelial cell lineages after suppression of oncogenic KRAS in claudin-low
mammary tumor cells. B. Comparative immunoblot analysis to validate the upregulation
of the luminal epithelial lineage and progenitor markers CD61 and GATA3 following
Dox-mediated ablation of oncogenic KRAS in three independent cell lines; GAPDH
serves as loading control. C. Flow cytometry-based analysis of CD24, CD49f, and CD61
cell surface marker expression in claudin-low mammary tumor cells before and after
Dox-mediated suppression of oncogenic KRAS. D. Comparative immunoblot analysis of
E- and N-cadherin, SLUG and SNAIL of independent cell lines before and after ligandmediated ablation of KrasG12D. E. Immunoblot analysis to assess changes in E-cadherin
expression following shRNA-mediated knockdown of SLUG in combination with Doxmediated suppression of oncogenic KRAS.
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Figure 3.19
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Figure 3.20 SLUG, SNAIL, and oncogenic RAS co-contribute to the suppression of
E-cadherin in claudin-low mammary cancer cells
A. Immunoblot analysis to assess expression changes in E-cadherin following shRNAmediated knockdown of SLUG and Dox-mediated ablation of oncogenic KRAS in three
independent WAP-Cre CAG-LSL-GFP EF1-LSL-tTA TetO-KrasG12D mammary tumor
cell lines. This blot validates the results shown in Figure 3.19E using a different hairpin
RNA against SLUG; GAPDH serves as loading control. B. Immunoblot analysis of Ecadherin and SLUG protein expression following shRNA-mediated knockdown of
SNAIL (TRCN0000218784) and Dox-mediated suppression of oncogenic KRAS.
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Figure 3.20
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Chapter 4: Discussion
4.1 The cell-of-origin is molecularly distinct from advanced claudin-low tumors
In his well-known textbook, Molecular Biology of the Cell, Albert Bruce states that most
cancers have characteristics that reflect their origin169. While this statement may hold true
for a considerable number of cancers, a substantial amount of literature has been
accumulating that contradicts this notion suggesting that the developmental path from the
cell-of-origin to the advanced malignant tumor stage might be more complex than
previously anticipated. A recent large-scale tumor study of 33 different cancer types
established that the classification of a tumor is not always determined by its presumed
cell-of-origin170. Particularly, breast cancers display substantial diversity in their
classification and previous studies have indicated that malignant breast cancer cells can
be vastly different from their cell-of-origin or their pre-malignant precursors. For
example, Lim et al.70 have shown that basal-like TNBCs that arise due to hereditary
BRCA1 alterations may originate from the luminal progenitor cell population. More
recent single-cell RNAseq studies have indicated that breast cancer cells can undergo a
subtype switch where the initial cancer cell shifts from a luminal A subtype in the
primary tumor to a HER2-enriched subtype in the metasteses171. In a few cases, a switch
from the HER2-enriched subtype to the basal-like subtype was also observed. The fact
that cancer cells are capable of subtype switching, even long after the tumor is
established, further supports the idea that the histological and molecular features of the
cell-of-origin might not be reflected in mammary tumors and their metastatic
descendants.
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Claudin-low breast cancers are characterized to be the least differentiated breast
cancer subtype and possess stem-like and mesenchymal features54. Because this subtype
closely resembles the normal, undifferentiated mammary stem cell (MaSC), it was
previously suggested that MaSCs give rise to claudin-low mammary tumors87. This
theory was likely based on the assumption that the mammary tumors closely resemble
their cell-of-origin, but this idea had not been experimentally validated due to the lack of
suitable in vivo models to study the tumor initiation and progression of claudin-low
mammary cancers.
In this work, we described the generation, histopathological analysis, and the
molecular characterization of three mouse models, two of which developed primary
claudin-low tumors with high incidences of metastasis. Through cell lineage tracing, we
demonstrated that oncogenic RAS signaling drives the initiation and progression of
triple-negative mammary cancers that originated in the luminal epithelium and evolved
into highly metastatic basal-like and claudin-low mammary cancers. Overall, our work
suggests that metaplastic tumors of the claudin-low subtype arise from differentiated
luminal epithelial cells that transition through a basal-like state and progressively gain
mesenchymal and stem cell-like characteristics (Figure 4.1). We demonstrate in vitro that
this process is partially reversible by ablating the expression of the oncogenic driver
KRASG12D, which cooperates with other molecular factors to maintain the mesenchymal
state. Recently, two groups have independently performed bioinformatic analyses on
human breast cancer data from the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC)160,172. In concordance with our findings, these in silico
analyses support the concept that claudin-low mammary cancers can arise from normal
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epithelial cell types other than undifferentiated MaSCs. While both of these groups
emphasized that claudin-low breast cancers display significant molecular diversity, their
proposal of how this diversity among this subtype arises is drastically different. Pommier
et al.172 proposed the separation of claudin-low breast cancers into three groups, where
each group arises from a distinct normal cell-of-origin. However, this data is based on the
assumption that claudin-low tumor cells preserve the characteristic of their cell-of-origin
and potentially neglects the possibility that a tumor might represent a transitional stage of
breast cancer development and not a final state. Based on our observations, each tumor is
much more likely to represent a snapshot in time of the cancer evolutionary process
rather than belonging to a distinct group that originates from a distinct cell type. The
longitudinal analysis of our genetically engineered mouse models is much more
supportive of a continuous developmental model where the claudin-low subtype
gradually emerges by passing through different developmental stages. This view is
supported by the bioinformatic analysis of Fougner et al.160 who conclude that the
emergence of the pure claudin-low subtype is likely based on a continuous process where
cancer cells progressively acquire increasing degrees of claudin-lowness. This continuous
process relies on the cellular plasticity of the neoplastic cells and is dependent on the
activation of an EMT program172.
It is important to note that the concern was recently raised that the claudin-low
subtype could be an artifact of extensive stromal and immune cell “contamination”160.
This idea is based on the assumption that the expression profile of tumor-infiltrating
mesenchymal stromal cells overshadows the expression profiles of the cancer cells and as
such presents as a separate subtype. However, because the cancer cells in our models are
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genetically labeled, we were able to assess the purity of cancer cells in mammary tumors
that were classified as claudin-low, and we found no significant amount of stromal cell
infiltration. All tumors showed a very high proportion of cancer cells and cells that
displayed a mesenchymal morphology were, in fact, cancer cells that must have arisen
from luminal cells.
In summary, our collective findings suggest that the cell-of-origin of claudin-low
mammary cancers can be vastly different from cells of the advanced mammary cancer
stage. Thus, we propose that claudin-low mammary cancers arise based on a gradual
developmental model where the luminal cell-of-origin progressively transitions through a
series of distinct stages to arrive at the claudin-low subtype.
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Figure 4.1. Highly metastatic claudin-low mammary cancers can arise from luminal
epithelial cells and maintain cellular plasticity mediated by oncogenic RAS signaling
and a RAS-independent EMT program. Figure was created with Biorender.com.
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Figure 4.1
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4.2. Hyperactive RAS signaling and EMT programs contribute to the initiation and
maintenance of claudin-low cancer cells
To date, subtype-specific genomic alterations have not been identified in claudin-low
breast cancers. However, hyperactivation of the RAS/MAPK pathway and genetic
alterations in tumor suppressors such as Trp53 and Cdkn2a seem to be a critical factor in
the development of this subtype. Mutations in TP53 are present in all seven human
claudin-low breast cancer cell lines reported by Prat et al.54. Three of these cell lines have
activating mutations in one of the RAS genes. One harbors a RAS-activating deletion in
the NF1 gene, and three have mutations in genes that are part of RAS/MAPK effector
pathways such as PI3K and PTEN (Table 4.1). A recent report by Pommier et al.172
showed that high activation of the RAS/MAPK signaling pathway is a recurrent feature
across all claudin-low breast cancers. Interestingly, the KRAS signaling gene-signature
was a predominant component of hallmark claudin-low pathways and showed
exceptionally high enrichment in claudin-low breast cancers that exhibited stem cell
features. Our work provides evidence that oncogenic RAS signaling is a direct
determinant for the initiation and maintenance of triple-negative mammary tumors that
progress towards the claudin-low subtype. It is evident that this gradual developmental
process is multifactorial and involves additional genetic alterations such as mutations in
tumor suppressors (e.g., Trp53) and epigenetic changes (e.g., suppression of Cdkn2a, and
elevated expression of EMT-related transcription factors). Moreover, primary and
metastatic tumor cells with mesenchymal characteristics were dependent on the persistent
expression of oncogenic RAS for tumor cell growth and survival in vivo. The finding that
claudin-low cancer cells rely on hyperactive RAS/MAPK signaling for their survival
might have important implications for the development of novel treatment regimens
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against this triple-negative breast cancer subtype. The potential efficacy of such a
treatment approach is supported by recent reports that show that human claudin-low
breast cancer cell lines are significantly more sensitive to MEK inhibition172. Our
findings are, therefore, an essential contribution as they establish the importance of
hyperactive RAS signaling for the initiation, maintenance, and survival of claudin-low
cancer cells in a biologically relevant setting in vivo.
Multiple studies have reported that hyperactive RAS signaling can activate the
EMT program in epithelial cells, which drives them into a more mesenchymal
phenotype173,174. As described previously, our longitudinal analyses of the claudin-low
cancer model showed that mammary tumors continuously acquire mesenchymal features
over the course of tumor development, which was accompanied by the gain of molecular
EMT characteristics such as loss of E-cadherin expression and high levels of N-cadherin.
We have also provided evidence in this study that this process is partially reversible by
ablating oncogenic RAS expression in claudin-low cell lines, which suggests that the
cellular plasticity of these mammary cancer cells is bi-directional and in part maintained
by the continuous hyperactivation of RAS. However, the cells were not able to undergo a
complete reversal as indicated by maintained N-cadherin expression and the continued
absence of E-cadherin in a subset of cells demonstrating that other RAS-independent
mechanisms take part in maintaining mesenchymal features on a molecular level. Our
work shows that two classical EMT transcription factors, SNAIL and SLUG, contribute
to the maintenance of molecular mesenchymal features in the absence of oncogenic RAS
signaling, but they are not solely responsible for upholding this differentiation state.
Thus, the continued upholding of the claudin-low mesenchymal differentiation state is
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multifactorial. It is conceivable that other EMT program components such as TWIST1,
TWIST2, ZEB1, and ZEB2 cooperate with hyperactive RAS, but exert their functions
independent of RAS activation. Further studies will be necessary to delineate what
additional RAS-independent factors contribute to the maintenance of mesenchymal
features. Preliminary data that we obtained (not shown here) indicates that Zeb1 and other
genes associated with EMT are upregulated in the absence of mutant RAS and thus need
to be examined more closely. Data presented by Pommier et al.172 support our notion that
claudin-low cancers with mesenchymal characteristics rely on hyperactive RAS signaling
and high activation of the EMT program. Their transcriptomic analysis of human breast
tumor samples from METABRIC and The Cancer Genome Atlas (TCGA) showed that
high RAS signaling coincides with enriched EMT pathway activation in claudin-low
breast cancers but is not observable in other intrinsic subtypes. While these observations
are correlative, we were able to provide evidence that oncogenic RAS signaling is a
direct determinant for the induction and maintenance of mesenchymal features through
activation of EMT pathway components but that other RAS-independent factors also
contribute to upholding this cellular state. The partial molecular return to a more
differentiated state upon ablation of some of these factors may support the concept that
mesenchymal claudin-low cancer cells are not locked into a particular cell fate but retain
cellular plasticity to potentially acquire characteristics that are distinct from their
mesenchymal differentiation profile.
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Table 4.1 Pathway alterations in bona fide human claudin-low cell lines
RAS-activating
mutation

RAS effector
mutations

TP53
mutation

CDKN2A
mutation

MDA-MB-436

No

No

Yes

No

Hs578T

Yes

Yes

Yes

Yes

BT549

No

Yes

Yes

No

MDA-MB-231

Yes

No

Yes

Yes

MDA-MB-157

Yes

No

Yes

No

SUM1315MO2

No

No

Yes

Yes

SUM159PT

Yes

Yes

Yes

No

Cell Line

4.3 The EF1-tTA model provides unique opportunities to study the true
developmental trajectories of cancer cells
Mouse models are a valuable tool to study human disease, especially when they closely
recapitulate the human disease counterpart. Interestingly, when Pfefferle et al.93
correlated a large number of mammary tumors that were derived from distinct mouse
models to human subtype equivalents, they discovered that mouse and human samples
were not always a molecular match. For example, the MMTV-neu mouse model showed
a strong correlation with the human luminal A subtype but not with the anticipated
HER2-enriched subtype. They further noted that most MMTV- or WAP-driven tumors
were luminal, which supports our previously stated notion that promoters whose natural
activity is limited to the luminal lineage likely force cancer cells that arise from this
compartment to maintain luminal characteristics due to lineage-dependent expression of
the oncogene. Such studies, together with our findings reported here, indicate that these
model systems have substantial limitations and highlight the importance of designing in
vivo models that do not perturb the true biology. Our team made significant advances to
overcome such limitations by developing the Cre-inducible EF1-tTA transgenic mouse
strain. We demonstrated that the EF1-tTA can be conditionally activated through Cre
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recombinase expression in a desired target cell population, thereby inducing a
constitutive expression of the tTA and its TetO effector transgene(s) that are independent
of the cellular identity. The effect this uncoupling of oncogene expression from a lineagerestricted promoter has is demonstrated by our observation that the MMTV-LTR, which
is preferentially expressed in luminal-type cells, likely restricted mutant-RAS-dependent
cancer cells to a more luminal fate, while the EF1-tTA-based model resulted in
mesenchymal and stem-like claudin-low mammary tumors that originated from bona fide
luminal cells. Hence, the cell fate-independent expression of oncogenic KRAS, mediated
by EF1-tTA, allowed the cancer cells to assume a developmental trajectory that was not
restricted to its cell-of-origin. We confirmed that this difference in developmental
trajectories is not due to variations in KRAS expression levels, nor is it likely to be
caused by distinct luminal populations that give rise to these neoplastic growths.
Evidence that the effects we observe are a result of uncoupling KRAS expression from its
luminal cell fate and independent of the targeted luminal cell population in these two
models is provided by the MMTV-Flp FSF-KrasG12D p53R172H murine strain. Both, the
MMTV-tTA and the MMTV-Flp utilize the same MMTV-LTR and therefore target the
same luminal cell population. However, the MMTV-Flp-induced mutant KRAS
expression gives rise to claudin-low mammary cancers, while the occurrence of this
subtype in the MMTV-tTA-based model is very rare. The difference between the two
models is that the MMTV-tTA-mediated expression of oncogenic KRAS is restricted by
the luminal cell fate, while the MMTV-Flp model expresses oncogenic KRAS from its
constitutively active endogenous locus. This indicates that luminal cell populations that
are targeted by the MMTV-LTR are capable of giving rise to claudin-low mammary

148

tumors but require the cell fate independent expression of oncogenic KRAS. Because
cells are not restricted in their developmental fate when oncogenic KRAS is driven by
EF1-tTA, we were able to observe the true transformative potential of the driver
oncogene with this model system. Mammary cancers that arise from the EF1-tTAmediated expression of oncogenic KRAS cluster within the claudin-low subtype.
Pfefferle et al. report that mouse mammary tumors that fall within this cluster show a
very high correlation with human claudin-low cancers93. No other group of mammary
cancers shows a more significant correlation of molecular features between mouse and
human samples than the claudin-low tumors. Interestingly, most murine models that can
give rise to claudin-low mammary cancers (e.g., DMBA-induced, or Trp53+/- irradiated)
are not under the control of oncogenes whose expression is tied to a cell-specific
promoter such as MMTV, WAP, or BLG (β-lactoglobulin), which further suggests that
cell fate independent expression of oncogenes might be necessary to accurately assess
their true biological effects. Future studies are warranted to assess whether other
oncogenes (i.e., Erbb2, Myc, Pik3) can give rise to claudin-low mammary tumors when
expressed under the control of EF1-tTA. Moreover, EF1-tTA activation could be targeted
to other cell lineages by expressing transgenes such as K14-CreERT2 (basal cells) or K8CreERT2 (luminal cells) to further validate our findings on the luminal origin of claudinlow mammary cancers.
In summary, the EF1-tTA strain has a wide spectrum of potential applications and
can be used to assess the natural impact of oncogenes on the developmental trajectories
of cancer cells. Our EF1-tTA-based claudin-low mammary cancer model does not only
allow us to study all stages of tumor progression, including the metastatic progression
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and cancer cell dormancy, it also closely reflects the human claudin-low breast cancer
subtype, making it the only triple-negative, claudin-low mammary tumor model to allow
for such studies.

4.4 Future objectives: Cancer cell dormancy, metastasis, and RAS effector pathway
activation of claudin-low mammary cancers
Patients with localized or regional breast cancer have a five-year relative survival rate of
above 85% (SEER). However, when breast cancer spreads to distant sites, this survival
drastically drops to less than 30%. With a 11.5% five-year relative survival rate, patients
with metastatic TNBC have by far the poorest outcome. These statistics highlight the
importance of metastatic breast cancer research. 30% of all primary TNBCs are classified
as claudin-low and, given the EMT-like and stem-like characteristics, it is presumed that
this subtype significantly contributes to the proportion of metastatic disease. Indeed, four
out of the seven human claudin-low cell lines in Table 4.1 have been derived from
metastatic sites. In this work, we presented the establishment of a murine model that
develops highly metastatic claudin-low triple-negative mammary cancers. The frequent
occurrence of pulmonary metastasis makes this model uniquely suitable for the study of
cancer cell dissemination mechanisms and therapy resistance of metastatic claudin-low
TNBCs. Not only do these mice form distant disease at secondary organ sites, with our
lineage-tracing and genetic labeling approach, we are able to visualize even micrometastatic lesions by evaluating the expression of GFP. Consequently, we have been able
to isolate even small GFP-positive metastatic lesions from fresh lung tissue and matching
primary mammary cancers. We aim to perform future studies that investigate the
molecular differences between the primary tumors and their metastatic descendants. Our
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group anticipates that such studies provide valuable insight into mechanisms that promote
metastatic dissemination and additionally may reveal enrichment of molecular pathways
in distant disease that make them susceptible to particular targeted therapeutic
interventions. The feasibility of such an approach has been demonstrated previously but
has not been used to evaluate claudin-low cancers and their metastatic descendants175,176.
Another important aspect to consider for improving the clinical outcome of
patients is dormant disease remaining in the patient after seemingly successful treatment.
Dormant disease can give rise to recurrent, and often treatment-resistant tumors at the
primary and metastatic sites. Investigation of dormant disease is dependent on in vivo
models as dormant cancer cells are rare, mostly undetectable in patients, and are known
to rely on microenvironmental signaling177. Here, we have shown that upon doxycyclinemediated ablation of oncogenic KRAS, mammary tumors and their metastatic
descendants macroscopically regress in vivo to a point where they are not visually
detectable anymore. However, microscopic examination of GFP expressing cells has
shown that a few residual cells survive long-term oncogene ablation. Previous studies
from our laboratory have observed a similar phenomenon in pancreatic cancer models
and we were able to identify mechanisms that confer resistance to targeted oncogene
ablation such as the upregulation of autocrine IGF1 signaling165,166. In the future, we aim
to investigate the residual dormant cancer cells that remain after targeted ablation of the
oncogene in our EF1-tTA-based claudin-low cancer model. Given the novelty of our
mouse model that allows for such studies, other studies have not been able to explore
dormancy mechanisms of this subtype. Preliminary findings (not reported here) have
indicated that the Jak1/Stat3 signaling axis might play a role in the survival of these
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cancer cells. We detected that this signaling pathway is enriched at the transcriptomic
level upon long-term ablation of oncogenic KRAS and confirmed by immunoblot that
active, tyrosine-phosphorylated Stat3 is significantly upregulated at the protein level.
Given the importance that Jak/Stat signaling has during normal mammary gland
development and cancer progression, we anticipate that this pathway might also
contribute to the survival and maintenance of dormant claudin-low cancer cells178-180.
Particularly active Stat3 signaling has been reported to drive stemness in cells, which
suggests that the Jak1/Stat3 signaling axis may contribute to stem cell characteristics and
potentially self-renewal capacity, which would be required for the dormant cancer cells to
give rise to tumors after escaping the dormancy state181. Because the Jak/Stat signaling
pathway is predominantly activated by extracellular signaling molecules (i.e., cytokines,
and peptide hormones) we aim to use single-cell RNAseq (scRNAseq) to determine the
signaling environment of the niche these dormant claudin-low cancer cells reside in as
well as cancer cell-intrinsic signaling mechanisms. Analysis of single cells is an unbiased
approach capable of displaying interactions of cancer cells with their microenvironment.
An additional area of interest that we aim to pursue is teasing out which major
RAS effector pathways might predominantly contribute to the development of the
claudin-low subtype. As described in the introduction of this work, RAS signals through
a wide variety of pathways to exert its effect on cells. For this purpose, we will use a
mouse model established by Musteanu et al.182 called RasE (Ras effector) which allows
for the sporadic activation of different combinations of three RAS effector pathways (i.e.,
MAPK, RALGEF, and PI3K). This sporadic activation occurs through transient
expression of Cre recombinase and can result in various activation combinations of the
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three RAS effector pathways. A total of 8 combinations are possible and can be screened
in the Cre activated tissue by PCR. We anticipate that when we combine the RasE model
with the WAP-Cre strain and induce WAP-mediated Cre expression in the luminal
mammary epithelium of female mice the subsequent development of mammary tumors
will reveal which combination of RAS effector pathway activation leads to claudin-low
mammary cancer development. Given the molecular profiles of the 7 human claudin-low
breast cancer cell lines (Table 4.1), we expect that MAPK and PI3K pathway activation
in combination or by themselves will likely result in claudin-low tumors but are not
excluding potential important effects by RALGEF.
In summary, the mouse models that we developed for this body of work are
valuable tools to study a wide variety of important biological questions that have to be
addressed to improve the survival of patients who present with claudin-low breast
cancers, particularly claudin-low TNBCs. Here we uncovered two fundamental features
of triple-negative claudin-low mammary cancers: (1) differentiated luminal epithelial
cells of the normal mammary gland can give rise to claudin-low mammary cancer with
mesenchymal and stem-like characteristics, and (2) this developmental trajectory is
initiated and largely maintained by the continuous hyperactivation of the RAS signaling
pathway and concurrent EMT pathway activation.
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